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1. Background 
1.1 History of endocannabinoid research 
Cannabis sativa, being botanically a member of the hemp family, has been cultivated for more 
than 5000 years both to obtain fibers for manufacturing of textiles and to provide a variety of 
extracts for medicinal and recreational use. Its stimluating and healing effects for conditions 
with fever, malaria, obstipation and rheumatic complaints are reported in ancient Chinese and 
ancient Arabic scripts (Hauer 2008). Since 300 A.D. it was observed that Cannabis can 
stimulate hunger and increase appetite. The psychomimetic activity of overdoses was 
described by the Chinese as “seeing the devil”, while the psychic activity was interpreted as a 
gift of god and the plant was considered holy in the Indo-European culture (Hiley et al. 2004). 
Cannabinoid research was largely neglected at the beginning of the 20th century, partly 
because of the political antimarijuana attitude, which officially started in the United States 
with the Harrison Act in 1914, leading to full prohibition 20 years later. From the past to the 
present, marijuana and other psychoactive derivatives of Cannabis sativa represent the most 
widely illegal drug consumed in the Western world. However, despite the social problems 
related to the abuse of these substances, scientific and social communities have recently 
started to get again aware of the therapeutic potentials of cannabinoids and of new synthetic 
compounds interfering with the endogenous cannabinoid system (Cota et al. 2003). In 1964 
Tetrahydrocannabinol (THC), the active ingredient of the cannabis plant and of marijuana, 
could be identified, but only at the beginning of the 1990s the receptor system was found, via 
which cannabis acts. Thus it also became possible to identify the endogenous ligands of this 
receptor system as well as to explore the endogenous system. These cannabinoids, which are 
built by the body itself, were named “endocannabinoids”. The first identified 
endocannabinoid arachidonylethanolamide was isolated from porcine brain in 1992 (Devane 
et al. 1992) and labelled “anandamide”. This name was derived from the Sanskrit term 
“ananda”, which means internal bliss (Cota et al. 2003). Up to the present besides several 
synthetic cannabinoids and natural derivatives of the hemp plant also some other endogenous 
ligands were described, from which 2-arachidonoylglycerol is the most known and so far 
most explored endocannabinoid. The importance of this system is also underlined by the 
finding of a high degree of evolutionary conservation across species, emphasizing the 
fundamental physiological role played by cannabinoids in brain function (De Petrocellis et al. 
1999). 
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1.2 Current state of knowledge of the endocannabinoid system 
1.2.1 Roles of the endocannabinoid system 
The endogenous cannabinoid system was mainly investigated in animals up to date. A myriad 
of physiological processes is being influenced by this system. The system, comprising 
specific receptors, endogenous ligands and degradation enzymes for the ligands, seems to act 
as a neuromodulatory system, influencing the activity of other neurotransmitter systems (Di 
Marzo et al. 1998).  
To get a first glimpse, cannabinoids are involved among others in antinociception, in 
locomotion, in inhibition of short-term memory (Lutz 2002), emotionality (Hill et al. 2009), 
cognition, feeding, regulation of neurotransmitter release, energy homeostasis and control of 
immune cell function (Graham et al. 2009).  
The endocannabinoid system has emerged as one of the most important facilitators of stress 
adaptation in the body (Finn 2010). Cannabinoid 1 (CB1) receptor knockout mice display an 
increased susceptibility to the anhedonic effects of chronic stress (Hill et al. 2009). Under 
conditions of acute stress, the endocannabinoid system tonically constrains activation of the 
HPA axis. During repeated exposure to aversive stimuli, the endocannabinoid system up-
regulates in limbic structures, resulting in neural activity in stress circuits, which could 
contribute to stress habituation (Gorzalka et al. 2008). The endocannabinoid-induced 
modulation of stress-related behaviors appears to be mediated, at least partly, through the 
regulation of the serotoninergic system (Haj-Dahmane et al. 2011).  
The cannabinoid system also plays an important role in the regulation of hormone secretion 
(Murphy et al. 1998). For instance, expression of the cannabinoid receptors and the synthesis 
of endocannabinoids in human pituitary cells, the ability of cannabinoids to inhibit prolactin 
and growth hormone secretion and to increase adrenocorticotropin (ACTH) secretion were 
described (Pagotto et al. 2001). The ability to modulate the hypothalamus–pituitary–adrenal 
(HPA) axis and the involvement in the stress-response are supported by a number of studies 
in which cannabinoid agonists were shown to produce anxiolytic effects in a dosedependent 
manner (Navarro et al. 1997).  
By enhancing serotonergic and noradrenergic transmission, increasing cellular plasticity and 
neurotrophin expression within the hippocampus, and dampening activity within the 
neuroendocrine stress axis, endocannabinoids exert antidepressant effects as well (Hill et al. 
2009). It seems also to be relevant for post-traumatic stress disorder (Varvel et al. 2007) by 
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accelerating the extinction of emotionally aversive memories (Ligresti et al. 2009), and for 
schizophrenia (Suarez et al. 2010). 
Cannabinoids seem to exert neuroprotective roles as well. In fact, endocannabinoids have 
been shown to promote neuronal maintenance and function (Hwang et al. 2010). There is 
growing evidence that the cannabinoid system may be important in the progression of 
neurodegenerative conditions including among others multiple sclerosis, epilepsy, 
Parkinson´s disease and Alzheimer´s disease(Graham et al. 2009). 
Additionally, the hippocampus has been reported to be a relevant neural substrate for 
cannabinoid-nicotine interactions (Viveros et al. 2007) and the endocannabinoid system is 
assumed to play a role in the general phenomenon of addiction (Lopez-Moreno et al. 2008). 
Furthermore, the cannabinoid system is able to modulate central regulation of body weight 
and adipose tissue function (Tonstad 2006). Immune and inflammatory responses and various 
further physiological functions, such as cardiovascular (Mendizabal et al. 2003), respiratory 
(Pfitzer et al. 2004), reproductive (Wenger et al. 2001), ocular function (Stumpff et al. 2005), 
anti-emesis or sleep (Hauer 2008) are being modified by the endocannabinoid system, too. 
Concerning conditions such as arthritis and osteoporosis, cannabinoids may help reduce 
cartilage resorption and joint destruction (Mbvundula et al. 2006) as well as maintaining bone 
mass and promoting bone growth (Bab et al. 2008). Other interesting properties of 
cannabinoids are represented by the antitumoral activity, for instance in breast cancer (Qamri 
et al. 2009) and in colon cancer (Cianchi et al. 2008). 
This overview demonstrates the wide range of physiological and pathophysiological processes 
in which the endocannabinoid system is involved, and hence the numerous medical fields for 
which it is highly interesting. 
1.2.2 Endogenous cannabinoids 
The most known and up to date best understood endocannabinoids are N -
arachidonoylethanolamine (anandamide) and 2-Arachidonoylglycerol (2-AG). There is 
evidence of other endocannabinoids: noladin (Njie et al. 2006), virodhamine (Porter et al. 
2002), oleamide (Hiley et al. 2007) and n-arachidonoyl-dopamine (Marinelli et al. 2007). The 
focus in the following will lie on 2-AG and anandamide, as these were the endocannabinoids 
investigated in our study.  
Anandamide and 2-AG are highly expressed in the brain and are also found in a number of 
peripheral tissues including heart, liver, kidney (Kondo et al. 1998), testis and blood. 
Endocannabinoids are fatty acid derivatives (Kamprath et al. 2009) (Figure 1).  
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Figure 1: Chemical structures of anandamide and 2-AG (Cota et al. 2003) 
 
In contrast to classical neurotransmitters, endocannabinoids are not stored in the interior of 
synaptic vesicles, because of the high lipophilicity of these ligands (Di Marzo et al. 1998). 
Anandamide and 2-AG are synthesized from lipid precursors on demand (McVey et al. 2003) 
and released from postsynaptic neurons. They serve as retrograde messengers at central 
synapses (Hashimotodani et al. 2007). The released endocannabinoids travel backward across 
the synapse (Wilson et al. 2001), activate presynaptic specific Gi-protein-coupled cannabinoid 
receptors (Di Marzo et al. 2002) on presynaptic terminals and modulate presynaptic functions. 
Retrograde endocannabinoid signalling is crucial for certain forms of short-term and long-
term synaptic plasticity at excitatory or inhibitory synapses in many brain regions 
(Hashimotodani et al. 2007). Endocannabinoids act like neurotransmitters – their release from 
neurons and nucleus containing blood cells is depolarization-mediated and they are rapidly 
removed from the extracellular space by means of an active membrane transport system 
(Hauer 2008). 
Anandamide binds both to CB1 receptor and CB2 receptor (Felder et al. 1995), with a higher 
affinity to CB1 receptor and is present at highest concentration in hippocampus, cortex, 
thalamus and cerebellum of different species including humans (Felder et al. 1996). 
 
The synthesis of anandamide takes place as follows: A phosphodiesterase, named 
phospholipase D, which is being activated by calcium ions, synthezises anandamide by the 
hydrolysis of a membrane phospholipid (N-arachidonoyl phosphatidyl ethanolamine=NArPE) 
(Di Marzo et al. 1994; Okamoto et al. 2004). This takes place intracellularly. The transport of 
the eminently lipophile anandamide to the extracellular space happens via a specific, largely 
unknown, membrane transport system on the principle of facilitated diffusion, from where it 
binds to the cannabinoid receptors and unfolds its effects (Figure 2) (Freund et al. 2003). 
Degradation of anandamide occurs in a two step process that includes transport into the cell 
by a specific transporter, followed by enzymatic hydrolysis into arachidonic acid and 
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ethanolamine by cytoplasmatic fatty acid amide hydrolase (FAAH) (Cravatt et al. 1996) in 
neurons and astrocytes. Therefore, anandamide levels can be eliminated rapidly (Wegener et 
al. 2009). The degradation products, arachidonic acid (AA) and ethanolamine, are re-
esterified to membrane phospholipids (Cota et al. 2003). 
 
 
Figure 2: Biosynthesis, release and inactivation of anandamide (Cota et al. 2003) 
Anandamide is synthesized from the phospholipase D - catalyzed hydrolysis of the membrane phospholipid 
precursor N-arachidonoyl phosphatidyl ethanolamine (NArPE) in neurons (1). After synthesis, anandamide is 
released from neurons through facilitated transport and binds to cannabinoid receptors (CB), leading to 
biological responses (2). The same carrier involved in the release, probably also mediates anandamide reuptake 
by neurons (3). After reuptake, the endocannabinoid is degraded through the action of the membrane-bound 
enzyme fatty acid amide hydrolase (FAAH) (4). Arachidonic acid (AA) and ethanolamine, produced from 
anandamide hydrolysis, are rapidly re-esterified to membrane phospholipids. 
 
2-AG represents the most abundant endocannabinoid in the brain (Stella et al. 1997). 
Identified in canine gut in a search for endogenous ligands selective for CB2 receptors, 2-AG 
displays a lower affinity for CB1 receptor than for CB2 receptor. 
2-AG is generated from diacylglycerol (DAG) by DAG lipase. DAG seems to be generated by 
sequential hydrolyses of inositol phospholipids (Ueda et al. 2011). As well as anandamide, 2-
AG can be metabolised by FAAH, nevertheless the hydrolysis of 2-AG via the enzyme 
monoacylglycerol lipase (MAGL) is more crucial in the brain (Dinh et al. 2002). It was found 
that approximately 85% of brain 2-AG hydrolase activity can be attributed to MAGL, and the 
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remaining 15% is mainly catalyzed by two previously unknown enzymes, ABHD6 and 
ABHD12 (Blankman et al. 2007). 
1.2.3 Cannabinoid receptors 
The endocannabinoid actions in the human body occur mainly through activation of an own 
receptor system, the cannabinoid receptors CB1 and CB2, but also through activation of other 
receptors, for instance the transient receptor potential vanilloid 1 (TRPV1) receptors (Howlett 
et al. 2000; Begg et al. 2005) and the recently de-“orphanized” receptor GPR55, which was 
suggested to be a novel cannabinoid receptor (Ryberg et al. 2007) a few years ago, and 
recently proven to modulate CB2 receptor mediated responses in human neutrophiles 
(Balenga et al. 2011). Additionally, the endocannabinoid system also interacts with NMDA-
receptors (Hampson et al. 2011) and dopamine-receptors (Pandolfo et al. 2011). The focus in 
this chapter will be on the CB1 and CB2 receptor system.  
In 1990, the first cannabinoid receptor (CB1) was cloned (Matsuda et al. 1990), followed 3 
years later by the characterization of a second cannabinoid receptor (CB2) (Munro et al. 
1993).  
 
CB1 receptors are mainly expressed in the brain, whereas CB2 receptors are found 
predominantly in the periphery primarily on cells of the immune system (Klein et al. 2003). 
More precisely, high densities of CB1 receptors are found within frontal regions of the 
cerebral cortex, basal ganglia, cerebellum, hypothalamus, hippocampus and the amygdala 
(Campolongo et al. 2009). They were also detected in reward circuits like nucleus accumbens 
and ventral tegmental area (Wegener et al. 2009). But CB1 receptors also exist in peripheral 
tissues: reproductive organs, heart, lung, gastrointestinum, ganglion of nervus sympathicus, 
bladder, adrenal (Pertwee 1997; Pertwee et al. 2002) and nociceptors in the skin (Agarwal et 
al. 2007).  
In contrast, CB2 receptors are situated predominantly on the B-cells and the natural killer 
cells of the immune system (Iversen 2003), where they modulate apoptosis and immunologic 
processes (Kaufmann et al. 2008).  
CB1 and CB2  receptors belong to the family of G-protein coupled receptors (GPCRs) 
(Devane et al. 1994) and are located at presynaptic terminals of neurons. CB1 receptors are 
abundant on GABAergic, glutamatergic and dopaminergic synapses (Wegener et al. 2009). 
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After activation of the CB1 receptor by endogenous (anandamide, 2-AG) or exogenous (THC) 
ligands, signalling events characteristic for GPCRs are caused, which finally result in 
reduction of neurotransmitter release from presynaptic terminals via several independent 
mechanisms. One of these mechanisms consists in inhibition of adenylate cyclase activity 
(Howlett et al. 1986), which entails in reduced cAMP formation, inhibition of protein kinase 
A (PKA) and finally in enhanced potassium ion - current into the synpatic cleft (Wegener et 
al. 2009). Further mechanisms are opening of inwardly rectifying potassium channels and 
closure of voltage-activated calcium channels (Felder et al. 1995). Over the G-proteins the 
CB1 receptors are coupled to ion channels, amongst others calcium channels. The modulation 
of these calcium channels leads to CB1 - mediated inhibition of presynaptic transmitter 
release (Figure 3). 
 
 
Figure 3: Signal transduction mechanisms affected by the CB 1 receptor in a presynaptic 
nerve terminal (e.g. on glutamatergic or GABAergic synapses) (Wegener et al. 2009) 
(1) Activation of the CB1 receptor by cannabinoids stimulates the coupling to a G-protein thereby initiating a 
series of intracellular events. (2) These events include activation of MAP kinase as well as inhibition of voltage-
dependent calcium channels and stimulation of inwardly rectifying potassium channels (KIR). The activation of 
A-type potassium channels is modulated via inhibition of adenylate cyclase activity, which leads to inhibition of 
protein kinase A (PKA) and finally to an enhanced outward potassium current. The consequence of CB 1 
receptor mediated modulation of cellular ion concentration is the inhibition of neurotransmitter release from 
synaptic vesicles (3), characterizing this receptor as important modulator of synaptic transmitter release and 
postsynaptic activity (4). 
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Diverse effects are mediated through several other systems, as for instance through the 
mitogen-activated protein (MAP) kinase pathway (Bouaboula et al. 1997), which regulates 
cellular functions such as cell growth, differentiation and apoptosis, as well as the expression 
of immediate early genes (Wegener et al. 2009). Dependent of the brain region, CB1 receptors 
can modify the release of noradrenaline, dopamine, g-aminobutyric acid (GABA), glutamate 
and serotonin (Schlicker et al. 2001). Besides, there are references indicating that the 
production of NO and arachidonic acid are being influenced as well (Pertwee et al. 2002). 
 
In contrast to CB1 receptor markedly less detail is known about CB2 receptor signalling. 
Unlike CB1 receptor, the CB2 receptor is inable to modulate calcium channels or potassium 
channels, but except for this difference the CB1 and CB2 receptors seem to display similar 
pharmacological and biochemical properties (Felder et al. 1995). 
1.2.4 Cannabinoid receptor ligands 
Besides the reviewed endocannabinoids anandamide and 2-AG several synthetic and plant-
derived cannabinoids exist which activate cannabinoid receptors, as well as pharmacological 
receptor ligands and receptor antagonists. These will be briefly outlined below for the sake of 
completeness. 
According to their chemical structures the cannabinoid receptor ligands are divided into four 
major classes. The first group includes the ‘classical’ cannabinoids, which have a like-3-ring 
structure (Cota et al. 2003). The cannabinoids from Cannabis plants (more than 60 different 
compounds, including D9-THC, D8-THC, cannabinol and cannabidiol) and several synthetic 
compounds, named HU (Horvath et al. 2011), are members of this group. The second group 
includes the so-called ‘nonclassical’ cannabinoids and comprises bi- and tricyclic analogs of 
D9-THC (Howlett et al. 2002). The third group consists of compounds named 
aminoalkylindols. The most representative member of this class is WIN-55,212, a CB1 
agonist widely used in experimental models (Howlett et al. 2002). The fourth group is 
represented by the endocannabinoids anandamide and 2-AG that are able to bind to 
cannabinoid receptors and to mimic the effects of plant-derived and synthetic cannabinoids. 
Remarkably, they are structurally not related to D9-THC. 
In the field of drugs the receptor antagonist rimonabant had been used as an anti-obesity agent 
for 2 years in Europe, but exhibited severe psychiatric side effects, such as increasing 
likelihood of depression and anxiety, leading to its withdrawal in 2008. Currently, 
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cannabinoid receptor antagonists, acting primarily in the periphery without crossing the 
blood-brain barrier are being developed (Wu et al. 2011). 
The drug dronabinol, which acts as a receptor agonist, was found to be potentially useful in a 
variety of medical conditions, while it notably has a very low abuse potential (Calhoun et al. 
1998). It can be used for the mitigation of anorexia (Morley 2002) for instance in cancer 
patients (similarly effective for the treatment of chemotherapy-induced nausea and vomiting 
as ondansetron) (Meiri et al. 2007), in aging long term care residents (Wilson et al. 2007) as 
well as in patients with HIV / AIDS (improves appetite and reverses weight loss) (Dejesus et 
al. 2007). In treatment of multiple sclerosis it displays an analgesic effect on central pain 
(Svendsen et al. 2004). For chronic pain patients who have significant pain despite constant 
doses of opioids, dronabinol may provide an additive effect on pain relief (Narang et al. 
2008). In a case report, dronabinol was described to be beneficial in a patient with cluster 
headache who was refractory to multiple acute and preventive medications (Robbins et al. 
2009). In Alzheimer´s disease there are results indicating a potential usefulness to improve 
disturbed behaviour (Volicer et al. 1997) (although it has to be noticed that this observation 
was made from only 3 patients). There are indications of dronabinol being an alternative in 
the treatment of intractable cholestatic pruritus (Neff et al. 2002). An interesting case report of 
a longlasting history of intracranial hypertension exists, in which clinical signs and symptoms 
disappeared after daily intake of dronabinol (Raby et al. 2006). In the field of ophtalmology, 
the cannabinoid dronabinol is known to reduce intraocular pressure, which may be relevant in 
the treatment of ocular circulatory disorders, includig glaucoma (Plange et al. 2007). A 
singular case report gives account of a pregnant woman with mitochondrial movement 
disorder, who benefited from dronabinol, especially by supported healthy maternal weight 
gain (Farooq et al. 2009), although the question of safety considering side effects on the 
newborn needs to be investigated more precisely. Grant et al. investigated dronabinol recently 
in the context of trichotillomania (Grant et al. 2011), as the substance has been supposed to 
reduce compulsive behaviour. In their study a significant reduction in trichotillomania 
symptoms without negative cognitive effects was observable. Lately, it has been found that 
dronabinol can be helpful as a substitution strategy for treatment of cannabis dependence, as it 
showed effectiveness concerning treatment retention and withdrawal symptoms in a 
randomized, double-blind, placebo-controlled, 12-week trial with 156 cannabis-dependent 
adults (Levin et al. 2011). 
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1.2.5 Neuroanatomy of the endocannabinoid system 
As described above the endocannabinoid system is an ubiqitous lipid signalling system which 
is involved in numerous regulatory functions, not only in the central nervous system but also 
in the autonomic nervous system, the endocrine system, the immune network, the 
gastrointestinal tract, the reproductive system and in microcirculation (Di Marzo et al. 1998). 
The distribution of elements of the endocannabinoid system in the nervous system is 
remarkable: in some regions, for example the hippocampus, there is a complementary 
distribution of cannabinoid receptors, endocannabinoid transporters and degradation enzymes. 
However, in other brain areas, for instance the thalamus, there are discrepancies in its 
distribution (i.e. transport activity and degradation enzymes in the absence of a relevant 
presence of the CB 1 receptors), which mirrors the present gaps in our knowledge of the 
composition of the endocannabinoid system (Rodriguez de Fonseca et al. 2005). 
High densities of CB1 receptors are found within frontal regions of the cerebral cortex, basal 
ganglia, cerebellum, hypothalamus, hippocampus and the amygdala (Campolongo et al. 
2009). They were also detected in reward circuits like nucleus accumbens and ventral 
tegmental area (Wegener et al. 2009). The density of CB 1 receptors in the anterior cingulate 
cortex (ACC) is moderately high (Glass et al. 1997). A significant up-regulation of CB 1 
receptor density and CB 2 receptor-stimulated G-protein activation was observed in prefrontal 
cortex of postmortem brains of depressed suicide victims (Hungund et al. 2004). 
The main endocannabinoids are derivatives of arachidonic acid (anandamide and 2-AG), 
which bind to G-protein-coupled receptors named CB 1 receptor and CB 2 receptor. While 
CB 1 is found densely in the brain related to motor control, cognition, emotional responses, 
motivated behaviour and homeostasis, CB 2 receptors are situated on B-cells and the natural 
killer cells of the immune system. Endocannabinoids are synthesized in a calcium-dependent 
manner and released upon demand from lipid precursors after cellular depolarization or 
receptor stimulation and serve as retrograde signalling messengers in GABAergic and 
glutamatergic synpases, and modulate postsynaptic transmission. They are transported into 
cells by a specific uptake system and are degraded by two specific enzymatic systems, the 
fatty acid amide hydrolase and the monoacylglycerol lipase. (Rodriguez de Fonseca et al. 
2005) Associated with the inhibitory action of endocannabinoids on presynaptic calcium 
channels is the inhibition of neurotransmitter release. This presynaptic inhibition of 
transmitter release by endocannabinoids may adopt two different forms of short-term synaptic 
plasticity. In the case of GABA transmission it is depolarization-induced suppression of 
inhibition (DSI) and in case of glutamate transmission it is depolarization-induced 
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suppression of excitation (DSE) (Wilson et al. 2002) (Diana et al. 2004). The contribution of 
endocannabinoids to these forms of short-term synaptic plasticity has been described in the 
hippocampus (Wilson et al. 2001) and the cerebellum (Diana et al. 2002). The role of the 
endocannabinoid-induced DSI or DSE appears to reflect the coordination of neural networks 
within the hippocampus and the cerebellum that are involved in physiological processes, such 
as memory (Rodriguez de Fonseca et al. 2005). Further forms of endocannabinoid modulation 
of synaptic transmission involve the induction of long-term potention (LTP) and long-term 
depression (LTD). Activation of the cannabinoid receptors prevents the induction of LTP in 
the hippocampal synapses (Stella et al. 1997) and a facilitation of LTD in the striatum 
(Gerdeman et al. 2002). 
Of special interest for our work is the role that endocannabinoids play in emotional 
processing. A key point for the endocannabinoid regulation of emotions is the amygdalar 
complex. There, endocannabinoids depress the release of glutamate and corticotropin-
releasing factor, reducing the amygdalar output and the activity of basolateral inhibitory 
GABA projections to the central nucleus of the amygdala, thereby activating the 
amygdalofugal pathway (Navarro et al. 1997). The result will lead to anxiety or anxiolysis, 
dependent on the rate of activation of descending projections of the ventral nucleaus of the 
amygdala to the hypothalamus and brain stem. Notwithstanding a a number of studies have 
showed that the response to enhanced cannabinoid transmission in the limbic system is 
anxiolysis (Cravatt et al. 2003) (Kathuria et al. 2003). 
As an interesting novel perspective concerning the perception of the endocannabinoid system 
is the thesis of a functional division between neuronal and glial elements of the 
endocannabinoid system. It was found that the functional neuroanatomy of the 
endocannabinoid system in the healthy brain appears to be quite different from that described 
unter pathological conditions. While CB 1 receptors and fatty acid amide hydrolase, together 
with the endocannabinoids and their putative uptake mechanisms, play essential roles in the 
normal state, profound changes occur under inflammatory insults. CB 2 expression seems to 
be induced in vivo in microglial cells, while fatty acid amide hydrolase is profusely expressed 
in astroglia. For instance, several groups have found significant increases in endocannabinoid 
levels in different animal models of human disease, such as amongst others multiple sclerosis 
(Baker et al. 2001), in which glia is assumed to play an important role. So it seems that a shift 
from mainly neuronal function of the endocannabinoid system to a major glial participation 
takes place under pathological conditions (Pazos et al. 2005). 
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1.2.6 Trauma and neurobiological sequelae  
1.2.6.1 Overview of neural circuits (amygdala, hippocampus and ACC) after 
trauma 
Hippocampal volumes of trauma survivors with post-traumatic stress disorder are reduced 
compared to those of nontraumatized persons (Yehuda 1999). Most studies noted that 
volumes of the right hippocampus are smaller than volumes of the left hippocampus in post-
traumatic stress disorder patients compared to healthy subjects (Pavic et al. 2007), although 
some studies report of bilaterally equal volume reductions. These abnormalities may represent 
a pretraumatic vulnerability to develop post-traumatic stress disorder or they may be a 
consequence of traumatic exposure. Apfel and colleagues measured hippocampal volumes in 
subjects with chronic post-traumatic stress disorder and subjects with remitted post-traumatic 
stress disorder: subjects with chronic post-traumatic stress disorder had, on average, a smaller 
hippocampus compared with those with remitted post-traumatic stress disorder (Apfel 2011). 
This again raises two possible conclusions: either a smaller hippocampus is a risk factor for 
lack of recovery from post-traumatic stress disorder, or traumatic effects on hippocampal 
volume are reversible once post-traumatic stress disorder symptoms remit and the patient 
recovers (Apfel 2011). Supporting the notion of reduced hippocampal volumes being a 
genetic vulnerability is a study with monozygotic twins discordant for trauma exposure 
(Gilbertson et al. 2002). On the other side, long-term treatment with paroxetine is associated 
with increased hippocampal volumes in post-traumatic stress disorder (Vermetten et al. 2003), 
making it unlikely that smaller hippocampal volumes represent exclusively a risk factor for 
the development of post-traumatic stress disorder. In Vietnam veterans hippocampal volume 
was directly correlated with combat exposure (Gurvits et al. 1996). Elevated sensitivity of the 
glucocorticoid receptor, associated with post-traumatic stress disorder, has been shown to lead 
to hippocampal volume loss, and this may explain the volume loss in PTSD (Yehuda 2001). 
Woon found in a meta-analysis of 39 hippocampal volumetric studies that hippocampal 
volume reduction is associated with trauma exposure independent of post-traumatic stress 
disorder diagnosis, although additional hippocampal reduction was found in post-traumatic 
stress disorder compared to the trauma-exposed group without post-traumatic stress disorder 
(Woon et al. 2010). A corresponding result has been reported by Winter (Winter et al. 2004).  
Besides hippocampal volume reduction also hippocampal function appears impaired among 
post-traumatic stress disorder patients (Nemeroff et al. 2006). The posterior hippocampus is a 
nodal point in storage, processing, and retrieval of spatiotemporal memories, central to the 
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protective function of fear conditioning. So smaller posterior hippocampi may indicate 
malfunction in this faculty, leading to the exaggerated conditioned fear response (Bonne et al. 
2008). Negative correlations were found between re-experiencing symptoms and left 
hippocampal volume (Lindauer et al. 2006). The stress-induced dysfunction of the 
hippocampus might mediate symptoms which are related to memory dysregulation, including 
explicit memory deficits as well as fragmentation of memory in abuse survivors (Bremner 
2006). 
 
Functional neuroimaging symptom provocation and cognitive activation paradigms using 
PET measurement of regional cerebral blood flow have revealed greater activation of the 
amygdala and anterior paralimbic structures (which are known to be involved in processing 
negative emotions such as fear), and failure of activation of the cingulate cortex (which is 
assumed to play an inhibitory role) in response to trauma-related stimuli in individuals with 
post-traumatic stress disorder. Functional MRI research has shown the amygdala to be 
hyperresponsive to fear-related stimuli in this disorder (Pitman et al. 2001) which may reflect 
the amygdala´s role in emotional memory and conditioned fear. Concerning amygdala 
volume, after the World Trade Center trauma.of 09/11/01 interestingly even healthy adults 
who were situated to the disaster with closer proximity had lower gray matter volume in 
amygdala after the incident (Ganzel et al. 2008). 
The amygdala is essential in memory for the emotional valence of events. Several 
neurological and psychological studies suggest that hyper-reactivity in the amygdala 
corresponds to a constellation of symptoms of anxiety in post-traumatic stress disorder, while 
the lowered activation of the prefrontal and the anterior cingular cortex could reflect slower 
extinction of a conditioned emotional response (Damsa et al. 2005). 
Regarding the influence of the endocannabinoid system on brain structures, a neuroprotective 
effect was described for the case of traumatic brain injury in the rat and the mouse 
(Mechoulam et al. 2002), as well as an essential role in acute fear adaptation for CB1 proteins 
in the amygdala of mice (Kamprath et al. 2011). 
 
Lower gray matter volume in the anterior cingulate after trauma (Ganzel et al. 2008) has been 
described, as well as decreased medial prefrontal / anterior cingulate function in post-
traumatic stress disorder (Bremner 2006). These brain regions comprise a neural circuit that 
has been demonstrated as important for emotional processing and emotional regulation, 
conditioned fear and attention on the one side, and in resilience to trauma on the other side. A 
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deficiency of medial prefrontal / anterior cingulate activation with re-experiencing of 
traumatic situations is hypothesized to represent a neural correlate of the failure of extinction 
known in post-traumatic stress disorder and subsequent re-experiencing and heightened 
arousal / vegetative reactions. The mentioned regulation of emotional responsiveness of the 
anterior cingulate gyrus is achieved through inhibition of amygdala function. Shin et al. found 
a correlation between increased amygdala function and decreased medial prefrontal function 
with traumatic reminders, suggesting a failure of inhibition of the amygdala by the medial 
prefrontal cortex which could account for increased post-traumatic stress symptoms with 
traumatic reminders (Shin et al. 2004). 
As far as the dorsal anterior cingulate cortex is concerned, hyperresponsivity during trauma 
script has been described (Nardo et al. 2011) and appears to be a familial risk factor for the 
development of post-traumatic stress disorder (Shin et al. 2011). In a script-driven trauma 
imagery study the symptom of avoidance was correlated negatively with anterior cingulate 
activity (Hopper et al. 2007). The anterior cingulate is part of the neural fear network and is 
an interface between emotion, cognition and behaviour. Accordingly, a reduced function of 
the anterior cingulate is associated with the inability to monitor and regulate emotional 
processes, such as fear, and furthermore inability to explain these rationally (Hull 2002). It 
has been postulated that resting state connectivity of the posterior cingulate with the 
perigenual anterior cingulate and the right amygdala is associated with current post-traumatic 
stress disorder symptoms and that correlation with the right amygdala predicts future post-
traumatic stress disorder symptoms (Lanius et al. 2010). 
Summarized, the three factors that are responsible for the symptoms in post-traumatic stress 
disorder are: stress sensitization, fear conditioning and failure of extinction. 
1.2.6.2 Endocannabinoids in the context of trauma 
One of the little clinical studies investigating endocannabinoid receptor mediated effects in 
humans after a trauma revealed the following result: out of 46 patients diagnosed with PTSD 
and having ongoing nightmares in spite of conventional antidepressants and hypnotics, 72% 
of patients experienced a cessation of nightmares or a significant reduction in nightmare 
intensity, as well as some patients reported reduced daytime flashbacks, after receiving the 
synthetic cannabinoid nabilone (Fraser 2009). Concerning aversive memories, it was found 
that deletion of CB1 receptors appears to selectively promote the consolidation and diminish 
the extinction of these (Hill et al. 2009). More precisely, findings suggest that 
endocannabinoids enhance memory consolidation in the basolateral amygdala and CB1 
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activity within this brain region is needed for enabling glucocorticoid effects on memory 
consolidation enhancement (Campolongo et al. 2009). According to the proposed role of the 
CB1 receptor as a ‘stress-recovery signal’ mediating receptor, CB1-agonists and inhibitors of 
endocannabinoid inactivation were found to facilitate the extinction of aversive memories in 
laboratory animals (Ligresti et al. 2009). The finding that CB1 antagonism in obese humans 
increases the odds of developing anxiety and depression (Despres 2009) indicates similar 
effects of the endocannabinoid system in humans. 
Another study states that the consolidation of aversive memories is modulated by the dorsal 
hippocampus endocannabinoid system, and that its recruitment seems to be mediated by 
glucocorticoids (de Oliveira Alvares et al. 2010). In this context, it is also interesting that 
among patients with PTSD, higher levels of cannabis consumption are observable, which 
might represent a form of self medication (Calhoun et al. 2000). On a genetical level, a 
number of variations in cannabinoid receptor genes in humans have been associated with 
PTSD (Onaivi 2009). 
Regarding the endocannabinoid system and psychic trauma, no further clinical studies have 
been published to date. Nonetheless the data outlined above demonstrate a crucial role of the 
endocannabinoid system in the context of trauma. 
Furthermore, a neuroprotective effect of endocannabinoids after traumatic injury has been 
hypothesized. Neurodegenerative stimuli result in increased endocannabinoid levels and 
animals with genetic deletions of CB1 receptors are more susceptible to the deleterious effects 
of such stimuli (Fowler et al. 2010). For instance, significantly elevated 2-AG levels were 
measured after closed head injury in mice and administration of synthetic 2-AG lead to 
significant reduction of brain oedema, reduced infarct volume and reduced hippocampal cell 
death compared with controls (Panikashvili et al. 2001). Not only 2-AG levels are 
significantly elevated after traumatic brain injury, but also CB2 receptors were shown to 
reduce infarct size (Shohami et al. 2011). On the other hand, also neurotoxic effects have been 
described (Sarne et al. 2011), of which future implications are being discussed and not clear 
yet. 
The endocannabinoid system has also been examined regarding its connection to the field of 
anxiety and fear. A growing body of evidence distinctively shows that deficits in 
endocannabinoid signalling may result in anxiogenic and depressive responses, while 
pharmacological augmentation of endocannabinoid signalling can produce anxiolytic as well 
as antidepressant responses (Hill et al. 2009). For instance, a study with mice demonstrated 
augmentation of the extinction of conditioned fear by facilitating endocannabinoid 
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neurotransmission (Chhatwal et al. 2005). In humans, the CB 1 receptor antagonist 
rimonabant exhibited severe psychiatric side effects, such as increasing the likelihood of 
depression and anxiety (Wu et al. 2011). When it comes to the issue of dose, interestingly low 
doses of a metabolically stable anandamide analog (methanandamide), microinjected into the 
prefrontal cortex, produced an anxiolytic-like response in rats, while higher doses induced 
anxiety-like behavior (Rubino et al. 2008). 
1.2.6.3 Endocannabinoids in the context of stress 
Coming to the relationship of the endocannabinoid system with stress, stress is defined as 
follows: 
“The term “stress” generally indicates an internal (i.e. infection, psychological condition) or 
external (i.e. physical danger or damage) circumstance that threatens the homeostasis of the 
organism. Thus, stress results in a discrepancy, either real or perceived, between the demands 
of a situation and the organism´s resources.” (Cota 2008)  
 
Results of previous studies on endocannabinoids and stress were mainly based on laboratory 
animal studies. 
One of the few studies in humans investigated the influence of somatic stress on the 
endocannabinoid system: in case of human chronic heart failure, a shift of the CB1 / CB2 
receptor ratio towards expression of CB2 receptors combined with significantly elevated 
peripheral blood levels of endocannabinoids indicating an activation of the endocannabinoid 
system was described (Weis et al. 2010). Another trial examined not the connection with 
stress itself, but the association with the sequelae of a stress reduction by loss of 
consciousness caused by general anaesthesia with isoflurane during cardiac surgery. This 
reduction in stress lead to significantly reduced plasma anandamide concentrations (Weis et 
al. 2010). 
Roughly summarized, the majority of studies with laboratory animals suggested that the 
endocannabinoid system possibly counteracts the harmful consequences of stressful stimuli 
(Resstel et al. 2009) and elicits anxiolytic-like effects (Kinsey et al. 2011). 
 
In order to scrutinize this issue more detailed, a distinction of acute stress and chronic / 
repeated stress makes sense. 
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Most of the research in animals suggests that acute stress produces a mobilization of 2-AG 
while concurrently reducing the tissue content of the other endocannabinoid ligand 
anandamide (Hill et al. 2010). Augmentation of endocannabinoid signalling seems to suppress 
stress-responsive systems (Hill et al. 2006). In a study with CB1 knockout mice, the lack of 
CB1 receptor resulted in an enhanced response to stress (Aso et al. 2008). Genetic and 
pharmacological studies demonstrate that a reduction in anandamide signalling may be 
involved in the initiation of HPA axis activation and reactions in emotional behaviour, while 
the increase in 2-AG signalling may be involved in terminating the stress response, limiting 
neuronal activation and contributing to changes in motivated behaviours (Hill et al. 2010). On 
the other side there is also contrary data in literature: emotionally stressful conditions in rats 
cause a reduction of 2-AG levels in the hypothalamus, without changes of the tissue levels of 
anandamide (Patel et al. 2004). Further work of Rademacher et al. in mice yielded reduced 
anandamide levels without affecting 2-AG levels after acute stress in the amygdala, without 
any changes of endocannabinoids in the medial prefrontal cortex and the ventral striatum 
(Rademacher et al. 2008). 
One possible explanation for diverging results was described by Hill and Bruce: a species 
difference appears to exist between the consequences of stress on the endocannabinoid system 
in mice and rats. In rats, stress was described to mobilize 2-AG signalling and to suppress 
anandamide signalling, in a variety of limbic structures. In mice, there does not appear to be 
an effect of stress on 2-AG (at least through the examination of tissue levels of 
endocannabinoid content), whereas the reduction in anandamide still seems to be present. 
The only investigation regarding the endocannabinoid system in humans after stress was 
conducted by Hill et al. by exposing 15 medication-free women diagnosed with major 
depression, and 15 healthy matched controls to the Trier social stress test (17 minutes mock 
job interview). Basal endocannabinoid levels were significantly reduced in women with major 
depression compared to matched controls, indicating a deficit in peripheral endocannabinoid 
activity. A rapid increase in circulating levels of 2-AG while not affecting circulating levels of 
anandamide was found after completion of the Trier social stress test in patients and controls, 
suggesting that stress-induced mobilization of 2-AG is similar in rats and humans (Hill et al. 
2009). 
 
Concerning chronic stress, existing data is controversial as well. Animal studies conducted by 
Taber and Hurley support the theory that a progressive increase of 2-AG and decrease of 
anandamide within limbic-related brain areas may, in part, mediate behavioral habituation to 
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repeated predictable stress (Taber et al. 2009). In accord with this hypothesis, Hill et al. could 
demonstrate one year later that the anandamide level is persistently decreased throughout the 
corticolimbic stress circuit in repeatedly stressed rats, whereas 2-AG is exclusively elevated 
within the amygdala in a stress-dependent manner (Hill et al. 2010). Similarly, there is further 
data suggesting that 2-AG may act at CB1 receptors in limbic brain regions to facilitate 
behavioural adaptation or habituation to repeated restraint stress (Finn 2010). Results of a 
mice study of Patel et al. indicate that exposure to repeated, but not acute, stress produces 
neuroadaptations that confer basolateral amygdala neurons with an enhanced capacity to 
elevate 2-AG content and engage in 2-AG-mediated short-term retrograde synaptic signalling 
(Patel et al. 2009). 
Patel and Hillard provided a thesis of endocannabinoid level changes after repeated stress 
dependent on the brain region. Two sets of brain regions with general patterns were described: 
a cortical-like pattern was observed within amygdala, hippocampus, the medial prefrontal 
cortex, and the hypothalamus. Within these regions, repeated stress induced an anandamide 
deficiency. In contrast to anandamide, 2-AG increased in these cortical-like structures, and 
displayed a sensitized response to repeated restraint stress. 
A contrary pattern was observed within the ventral striatum, assigned to a subcortical pattern: 
here data indicated that repeated restraint results in a 2-AG deficit together with enhanced 
anandamide signalling (Patel et al. 2008). 
Derived from a male mice model, it was hypothesized in that increased CB1 receptor activity 
contributes to the process of habituation to homotypic stress (Patel et al. 2005). In the 
following years this was corroborated, which is outlined in a paper of Gorzalka: under 
conditions of repeated stress, a progressive increase in limbic 2-AG / CB receptor signalling 
contributes to the development and expression of neuroendocrine habituation (Gorzalka et al. 
2009). Interestingly, the relationship between glucocorticoids and the endocannabinoid 
system appears to be functionally bidirectional: not only anandamide signalling influences the 
HPA axis, but also the CB1 receptor is under negative regulation of glucocortidoids in the 
hippocampus, which suggests that hippocampal CB1 receptor signalling might be reduced 
under conditions associated with hypersecretion of glucocorticoids, such as chronic stress 
(Hill et al. 2008). Correspondingly, downregulation of CB1 receptor expression and 2-AG 
levels within the hippocampus under chronic stress was described in an animal study (Hill et 
al. 2005). In an animal study, Hill et al. reported a downregulation of CB1 receptor expression 
and 2-AG levels within the hippocampus under chronic stress, while interestingly CB1 
receptor density and 2-AG content were unaffected in the limbic forebrain (Hill et al. 2005). 
 24 
Regarding the nature of repeated stress, Campos et al. conducted a study with rats suggesting 
that facilitation of the endocannabinoid system in the ventral hippocampus regulates anxiety-
like behaviors and that this effect is dependent of previous stress experience (Campos et al. 
2010). Taking early maternal deprivation as a model for neurodevelopmental stress, an 
investigation in rats provided evidence for a connection of early maternal deprivation with 
dysregulation of the endocannabinoid system, in terms of significant increase in DAGLalpha 
immunoreactivity (enzyme involved in 2-AG biosynthesis) and decrease in MAGL 
immunoreactivity (enzyme involved in 2-AG degradation) (Suarez et al. 2010). Gender might 
have an influence on the endocannabinoid system in chronic unpredictable stress, as the 
endocannabinoid system is preferentially organized in male and female animals to respond 
differentially to chronic stress (Reich et al. 2009). 
An interesting theory is the following postulated by Carrier et al.: they report of direct and 
indirect evidence that stress affects endocannabinoids, whereas chronic stress affects CB1 
receptor density (Carrier et al. 2005). 
 
Taken together, the picture of the endocannabinoid system is largely one of a system that 
serves to facilitate habituation to stress, reduce innate anxiety responses, promote extinction 
of conditioned fear responding to unconditioned and conditioned stress, as well as diverse 
effects on memory and plasticity (Abush et al. 2010).  
In other words, the endocannabinoid system promotes activities and responses which are 
beneficial for survival in the face of challenges to homeostasis (Finn 2010). Moreover, there is 
evidence that among others the central amygdala is an important neural substrate mediating 
the interactions between cannabinoids and environmental stress (Patel et al. 2005). 
2. Research objectives 
Given that post-traumatic stress disorder is an anxiety disorder characterized by 
reexperiencing intrusive recollections of the traumatic event in ways that are highly 
distressing (Yehuda 2004), agents which are beneficial in the extinction of aversive 
memories, such as facilitators of endocannabinoid signalling, may exhibit a therapeutic 
benefit in PTSD (Hill et al. 2009). 
So far, little to no research took place concerning endocannabinoid response to stress in 
humans. In this study we investigated the influence of a type I traumatic event on the 
endocannabinoid system in humans over the course of time. We measured plasma 
endocannabinoid levels in subjects who experienced a psychic trauma and compared these to 
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non-traumatized controls. The goal was to contribute to the understanding of the role the 
endocannabinoid system plays in pathophysiological processes on one hand, and get first 
indications for the endocannabinoid system as a potential therapeutic target on the other hand. 
Moreover, based on previous findings of structural alterations of distinct brain regions, e.g. 
the hippocampus, we have analyzed peripheral endocannabinoid levels in relation to structural 
changes in key regions of the brain using MRI and voxel based morphometry. 
3. Materials and methods 
3.1 Participants and setting 
Participants were 4 women and 10 men who were admitted to the outpatient clinics of the 
Munich University Psychiatric Hospital and the Munich University Department of Surgery . 
All participants had experienced a type I trauma, i.e. a single trauma of short duration, 
provoked by an accidental cause. Eleven of the participants were underground / streetcar / city 
train drivers and traumatized by experiencing a suicidal jump of an unknown person in front 
of their train. Further three cases were as follows: In one case a pedestrian was hit by a 
streetcar, in another case a pedestrian was struck by a car and one case was an occupational 
accident (Table 1). 
The participants were between 29 and 58 years of age, with a mean age of 44.5 years. The 
control group consisted of healthy non-traumatized subjects matched for age and gender. 
There were no significant differences in age, sex, psychiatric history, psychiatric family 
history or history of addiction between the two groups (Table 2). 
 
Subject Role / Profession Accident 
1 Streetcar driver Suicidal jump in front of streetcar driver 
2 Underground train driver Suicidal jump in front of underground train driver 
3 Pedestrian Pedestrian struck by car 
4 Workman Occupational accident (falling down a ventilation shaft) 
5 Pedestrian Pedestrian struck by streetcar 
6 Streetcar driver Suicidal jump in front of streetcar driver 
7 Underground train driver Suicidal jump in front of underground train driver 
8 Underground train driver Suicidal jump in front of underground train driver 
9 Streetcar driver Suicidal jump in front of streetcar driver 
10 Streetcar driver Suicidal jump in front of streetcar driver 
11 Underground train driver Suicidal jump in front of underground train driver 
12 Streetcar driver Suicidal jump in front of streetcar driver 
13 City train driver Suicidal jump in front of city train driver 
14 Streetcar driver Suicidal jump in front of streetcar driver 
Table 1: Type of traumatic experience 
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Demographics Trauma Control Statistics 
Age (SD) 44.50 (8.25) 
43.36 
(8.56) n.s. 
Gender (male/female) 10/4 10/4 n.s. 
Years of education 14 15 n.s. 
Marital status (single, married, divorced) 2/12/0 4/7/3 n.s. 
Psychiatric history  4 0 n.s. 
Psychiatric family history 4 3 n.s. 
Substance abuse history (> 10 years prior to study) 5 1 n.s. 
Regular intake of any medication 8  4 n.s. 
Somatic history 9 1 p=0.004 
Past traumata (yes/no) 7/7 0/14 p=0.006 
Table 2: Demographic and clinical variables 
 
Participants were evaluated within fourty-eight hours after the traumatic event, one month 
later and six months later. Controls were evaluated analogously (Figure 4). At each point of 
time a psychiatric interview was conducted by an experienced psychiatrist and the Clinician 
Administered PTSD Scale (CAPS) was administered to the participants. Depressive 
symptoms were surveyed with Hamilton Depression Scale (HAMD) and Becks Depression 
Inventory (BDI). Acute stress disorder and PTSD were diagnosed according to DSM-IV 
criteria. “Subthreshold PTSD” was diagnosed according to Stein et al.: presence of at least 
one symptom of the reexperiencing cluster plus either three symptoms or more of the 
avoidance cluster or at least two symptoms of the hyperarousal cluster (Stein et al. 1997). 
Endocannabinoid measurements (anandamide and 2-AG) were performed at all three points of 
time in traumatized and controls. Furthermore, subjects underwent MRI scanning at all three 
time points using diffusion tensor imaging and voxel-based morphometry of amygdala, 
hippocampus and cingulum. Detailed results of these investigations are reported in a separate 
dissertation (Dino Santangelo de Souza). 
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Figure 4: Study design 
 
The study was approved by the local ethics committee of the Faculty of Medicine Ludwig-
Maximilians-University Munich, Germany and carried out in accordance with the 
Declaration of Helsinki. Patient confidentiality was in no way breached and a statement of 
written informed consent was made before starting examination. 
3.2 Endocannabinoid measurement 
Blood samples for endocannabinod measurements were drawn into EDTA containing tubes 
(S-Monovette®, Sarstedt, Numbrecht, Germany) and centrifuged immediately (within five 
minutes). The time interval between blood sampling and centrifugation was minimized as 
previous experiments have shown that endocannabinoid generation in blood samples is 
continued ex-vivo, which could lead to false positive increases in measured plasma 
endocannabinoid concentrations. 
Peripheral endocannabinoid activity was determined by measuring the endocannabinoids 
anandamide (ANA) and 2-AG in plasma using high performance liquid chromatography-
tandem mass spectrometry (HPLC / MS-MS). Measurements followed automated on-line 
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solid phase extraction using column switching with subsequent direct transfer to HPLC and a 
tandem mass spectrometry system (Waters Quattro Ultima Pt; Waters Corporation, 34 Maple 
Street, Milford, MA 01757, USA). Stable isotope labeled anandamide (fourfold deuterated) 
was synthesized by Roche Diagnostics, Mannheim, Germany and fivefold deuterated 2-AG 
was obtained from Cayman Europe, Tallinn, Estonia. These compounds were used as the 
internal standard for HPLC / MS-MS measurements. The purity of these materials amounts 
>97.2%. Pure solutions of anandamide (0.1 to 2 ng/ml) and 2-AG (0.5 to 10 ng/ml) were 
applied for calibration. Anandamide and 2-AG were supplied by Sigma, Deisenhofen, 
Germany. Electrospray ionization in the positive mode was used; the following mass 
transitions are monitored: native anandamide, 348 > 62; 4d3 anandamide (internal standard), 
352>66. The method has a linear response within the calibration ranges and a total 
coefficient of variation of 34% at a mean concentration of 0.2 ng/l. The lower limit of 
detection of the method (defined as a signal / noise ration > 4:1) was 0.025 ng/ml for 
anandamide and 0.33 ng/ml for 2-AG. 
3.3 Data processing for volumetric data analysis 
The analysis was done using SPM5 and a code written in Matlab R2007a. Initially the 
DICOM pictures were converted via MRIcro® (Version 1.39 on Linux) to the Analyze 
format. Anatomical parcellation was semi-automatically performed on the basis of high-
resolution MPRAGE data using IBASPM (Individual Brain Atlas using Statistical Parametric 
Mapping Software), a specialized toolbox for the statistical parametric mapping package 
(SPM 5, J. Ashburner an K.J. Friston, Wellcome Department of Imaging Neuroscience, 
UCL, London). The software uses a standardized procedure. Three principal elements for the 
labeling process are used: gray matter segmentation, normalization transform matrix (that 
maps voxels from individual space to standardized one) and MaxPro MNI Atlas. All three 
are combined to yield a good performance in segmenting gross cortical structures. The 
programs here can be used in general for any standardized Atlas and any MRI image 
modality. In a first step the MRI volume is normalized to MNI (Montreal Neurological 
Institute) space using a set of non-linear basis functions to obtain the spatial transformation 
matrix. After that individual images are segmented in three different brain tissues: cerebral 
spinal fluid, grey matter and white matter. Thereafter each individual grey matter voxel is 
labelled based on MNI anatomical atlas and the transformation obtained in the previous step. 
For further analysis the resulting volumetric data were transferred to SPSS 14.0® (SPSS Inc., 
Chicago, Illinois, USA). (Each of the regions-of-interest (ROI) volumes is depicted in cm³.) 
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The three work steps of MRI acquisition, image preprocessing and analysis of imaging data 
will be described in detail in the doctor´s thesis of the colleague (Dino Santangelo de Souza) 
who performed these steps (ditto for the three investigated key regions, which were selected 
according to literature). 
3.4 Data analysis 
Analyses were performed in SPSS, Version 17.0. Traumatized subjects and controls were 
compared for differences in demographic and clinical variables at baseline using exact fisher 
tests for categorical variables and t-tests for dimensional variables. Endocannabinoid levels 
and psychometric scales over the three points of time were analyzed for change with a 
repeated-measures design (ANOVA), testing for main effects of time and group as well as 
time x group interactions. Hippocampal and amygdala volumes were correlated with 
endocannabinoid levels by use of Pearson correlation. All statistical tests were two-tailed. 
4. Results 
4.1 Description of groups 
There were no significant differences in demographic and clinical variables between both 
groups apart from somatic history (p=0.004) and past traumata (p=0.006) (Table 2). Fourty-
eight hours after trauma all subjects met the criteria for an acute stress disorder. One month 
later, four subjects had developed a PTSD (PTSD), in four subjects subthreshold PTSD 
criteria were met and six subjects were free of symptoms. After six months, only one subject 
was still suffering from PTSD and thirteen subjects were free of symptoms. 
4.2 Psychometric measures 
CAPS, HAMD and BDI scores are shown in Table 3. In the trauma group, there were 
significant differences in CAPS scores over the three points of time (p=0.00, df=2.0, F=39.21 
ANOVA). HAMD and BDI scores did not change significantly over the course of time. There 
were significant differences between the subject group and the control group in CAPS scores 
at all points of time (p=0.00, df=1.0, F=22.63 ANOVA). HAMD (p=0.004, df=1.0, F=10.25, 
ANOVA) and BDI (p=0.018, df=1.0, F=6.49, ANOVA) scores did significantly differ 
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between both groups at fourty-eight hours and one month after trauma. After six months there 
were no statistically significant differences in HAMD and BDI scores between both groups. 
 
 
CAPS  HAMD  BDI  Anandamide 
[ng/ml] 
2-AG 
[ng/ml] 
Subjects 
   
 
 
   48 Hours  57 (31.0) 14 (7.6) 10 (11.5) 0.14 (0.1) 13.62 (13.0) 
   1 Month  37 (35.0) 12 (11.1) 9 (9.3) 0.15 (0.1) 14.11 (10.1) 
   6 Months  25 (31.2) 9 (10.8) 7 (8.9) 0.15 (0.1) 11.22 (8.60) 
Controls 
   
  
   48 Hours  0 (0) 2 (2.6) 2 (4.0) 0.12 (0.0) 7.76 (5.8) 
   1 Month  0 (0) 1 (2.7) 3 (3.9) 0.14 (0.1) 6.71 (3.3) 
   6 Months  0 (0) 2 (3.6) 2 (3.3) 0.11 (0.1) 6.71 (4.3) 
Table 3: Synopsis of CAPS and depression scores together with plasma concentration of 
anandamide and 2-AG. Mean (SD) values are shown. 
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4.3 Endocannabinoid levels 
Table 4 shows 2-AG and anandamide levels of individual subjects and controls. 
 
Group No. ANA  
48h 
[ng/ml] 
ANA  
1 month 
[ng/ml] 
ANA  
6 months 
[ng/ml] 
2-AG  
48 h 
[ng/ml] 
2-AG  
1 month 
[ng/ml] 
2-AG  
6 months 
[ng/ml] 
Subject 1 0.33 0.21 0.21 12.10 20.80 11.70 
2 0.14 0.25 0.16 19.80 36.20 21.80 
3 0.22 0.22 na 12.70 15.30 na 
4 0.03 0.06 0.05 2.83 2.27 2.48 
5 0.03 0.10 na 1.03 3.68 na 
6 0.19 0.16 0.06 8.92 13.70 7.50 
7 0.15 0.18 0.10 30.30 12.60 13.00 
8 0.07 0.11 0.20 6.69 5.41 3.29 
9 0.18 0.20 0.20 49.90 30.30 30.30 
10 0.13 0.13 0.08 13.30 5.06 5.93 
11 0.20 0.15 0.14 14.90 15.60 19.00 
12 0.07 0.09 0.21 9.10 19.00 10.60 
13 0.11 0.14 0.35 6.16 13.40 5.26 
14 0.17 0.07 0.06 3.01 4.27 3.77 
 
    
   
1 0.12 0.24 na 20.30 13.50 na 
2 0.09 0.14 0.12 15.70 7.06 13.50 
3 0.16 0.10 0.07 3.24 6.14 4.86 
4 0.13 0.10 0.08 7.23 7.13 7.23 
5 0.13 0.08 0.06 5.67 7.14 3.90 
6 0.14 0.13 0.10 9.70 4.23 4.23 
7 0.20 0.15 0.17 14.80 8.92 7.94 
8 na 0.15 0.08 na 4.20 1.78 
9 0.10 0.08 na 2.59 2.02 na 
10 0.08 0.09 0.11 1.25 4.84 1.84 
11 0.08 0.08 0.07 3.36 8.49 11.40 
12 0.10 0.08 0.07 4.34 1.89 3.37 
13 0.07 0.11 0.17 4.95 12.00 6.42 
Control 
14 0.18 0.38 0.22 7.69 6.39 14.00 
Table 4: Anandamide and 2-AG levels (ng/ml) of individual subjects and controls (na – not 
assessed) 
 
Regarding endocannabinoid levels over the course of time, an analysis of variance was 
calculated. On the first level no significant results were found, so an exploratory post hoc 
analysis was performed. Time effect for 2-AG was not significant (p=0.103, df=2.0, F=2.55, 
ANOVA, Multivariate Tests). Regarding group x time interaction effect, 2-AG decreased in 
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the trauma group between one month and six months after trauma (p=0.051, df=2.0, F=3.47, 
ANOVA, Multivariate Tests). In non-traumatized controls, there were no statistical 
differences in 2-AG and anandamide levels over the course of time (Table 3, Figure 5 and 6).  
 
As group effects are concerned, 2-AG levels were compared between subjects and controls: 
there was a statistical significant difference one month after trauma (p=0.046, df=1.0, F=4.49, 
ANOVA, Tests of between-subjects effects). At fourty-eight hours after trauma and six 
months after trauma there were no statistical differences in 2-AG levels between both groups 
(Figure 5). Concerning anandamide levels there were no statistical differences at any point of 
time between traumatized and non-traumatized (Figure 6). 
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Figure 5: 2-AG over the course of time for both groups (mean, 95% Gaussian confidence 
intervals) 
p=0.046 
 34 
 
Figure 6: Anandamide over the course of time for both groups (mean, 95% Gaussian 
confidence intervals) 
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4.4 Correlations between endocannabinoid levels and 
Demographics / psychometric scales 
No considerable significant correlations were found between endocannabinoid levels and 
Demographics (Anandamide: Tables 5-9, 2-AG: Tables 10-14) / clinical variables (CAPS, 
HAMD, BDI) (Anandamide: Table 15, 2-AG: Table 16). 
 
 
Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.252 -.308 
Gender 
Sig. (2-tailed) .384 
14 
.306 
13 
Correlation 
Coefficient 
.010 .362 
48 hours  
after trauma 
Age 
Sig. (2-tailed) .972 
14 
.224 
13 
Correlation 
Coefficient 
-.136 -.198 
Gender 
Sig. (2-tailed) .644 
14 
.496 
14 
Correlation 
Coefficient 
.274 .002 
1 month  
after trauma 
Age 
Sig. (2-tailed) .343 
14 
.995 
14 
Correlation 
Coefficient 
-.035 -.009 
Gender 
Sig. (2-tailed) .915 
12 
.977 
12 
Correlation 
Coefficient 
.022 .043 
6 months 
after trauma 
Age 
Sig. (2-tailed) .946 
12 
.895 
12 
Table 5: Correlations between anandamide plasma levels and gender / age during the 6-
months follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
.482 -.070 
Past traumata 
Sig. (2-tailed) .081 
14 
.820 
13 
Correlation 
Coefficient 
-.456 a 
48 hours  
after trauma 
Somatic injury 
Sig. (2-tailed) .101 
14 
 
13 
Correlation 
Coefficient 
.340 .121 
Past traumata 
Sig. (2-tailed) .234 
14 
.680 
14 
Correlation 
Coefficient 
-.663** a 
1 month  
after trauma 
Somatic injury 
Sig. (2-tailed) .010 
14 
 
14 
Correlation 
Coefficient 
.311 .184 
Past traumata 
Sig. (2-tailed) .325 
12 
.568 
12 
Correlation 
Coefficient 
-.516 a 
6 months 
after trauma 
Somatic injury 
Sig. (2-tailed) .086 
12 
 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
a. Cannot be computed because at least one of the variables is constant. 
Table 6: Correlations between anandamide plasma levels and past traumata / somatic injury 
during the 6-months follow-up period after trauma. Traumatized subjects are compared to 
non-traumatized controls. 
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.225 a 
Psychiatric history 
Sig. (2-tailed) .440 
14 
 
13 
Correlation 
Coefficient 
.496 .374 
48 hours 
after trauma 
Somatic history 
Sig. (2-tailed) .071 
14 
.208 
13 
Correlation 
Coefficient 
-.073 a 
Psychiatric history 
Sig. (2-tailed) .805 
14 
 
14 
Correlation 
Coefficient 
.255 .110 
1 month 
after trauma 
Somatic history 
Sig. (2-tailed) .378 
14 
.707 
14 
Correlation 
Coefficient 
.257 a 
Psychiatric history 
Sig. (2-tailed) .420 
12 
 
12 
Correlation 
Coefficient 
.212 -.393 
6 months 
after trauma 
Somatic history 
Sig. (2-tailed) .508 
12 
.207 
12 
a. Cannot be computed because at least one of the variables is constant. 
Table 7: Correlations between anandamide plasma levels and psychiatric history / somatic 
history during the 6-months follow-up period after trauma. Traumatized subjects are 
compared to non-traumatized controls. 
 
 
Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.012 .050 Intake of any 
medication Sig. (2-tailed) .969 
14 
.871 
13 
Correlation 
Coefficient 
.181 -.305 
48 hours  
after trauma 
Substance abuse 
history Sig. (2-tailed) .536 
14 
.311 
13 
Correlation 
Coefficient 
-.139 .244 Intake of any 
medication Sig. (2-tailed) .636 
14 
.401 
14 
Correlation 
Coefficient 
-.237 .114 
1 month  
after trauma 
Substance abuse 
history Sig. (2-tailed) .415 
14 
.698 
14 
Correlation 
Coefficient 
.188 -.252 Intake of any 
medication Sig. (2-tailed) .559 
12 
.429 
12 
Correlation 
Coefficient 
-.467 .244 
6 months 
after trauma 
Substance abuse 
history Sig. (2-tailed) .126 
12 
.444 
12 
Table 8: Correlations between anandamide plasma levels and intake of any medication / 
substance abuse history during the 6-months follow-up period after trauma. Traumatized 
subjects are compared to non-traumatized controls.  
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.261 -.461 
Marital status 
Sig. (2-tailed) .368 
14 
.113 
13 
Correlation 
Coefficient 
.179 -.060 
48 hours  
after trauma 
Psychiatric family 
history Sig. (2-tailed) .540 
14 
.846 
13 
Correlation 
Coefficient 
-.014 -.138 
Marital status 
Sig. (2-tailed) .962 
14 
.639 
14 
Correlation 
Coefficient 
.049 .196 
1 month  
after trauma 
Psychiatric family 
history Sig. (2-tailed) .867 
14 
.502 
14 
Correlation 
Coefficient 
-.266 .192 
Marital status 
Sig. (2-tailed) .403 
12 
.549 
12 
Correlation 
Coefficient 
-.341 .323 
6 months 
after trauma 
Psychiatric family 
history Sig. (2-tailed) .278 
12 
.305 
12 
Table 9: Correlations between anandamide plasma levels and marital status / psychiatric 
family history during the 6-months follow-up period after trauma. Traumatized subjects are 
compared to non-traumatized controls. 
 
 
Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.233 -.053 
Gender 
Sig. (2-tailed) .422 
14 
.863 
13 
Correlation 
Coefficient 
-.152 .271 
48 hours  
after trauma 
Age 
Sig. (2-tailed) .604 
14 
.370 
13 
Correlation 
Coefficient 
-.218 -.428 
Gender 
Sig. (2-tailed) .455 
14 
.127 
14 
Correlation 
Coefficient 
.029 .007 
1 month  
after trauma 
Age 
Sig. (2-tailed) .922 
14 
.982 
14 
Correlation 
Coefficient 
-.161 -.026 
Gender 
Sig. (2-tailed) .618 
12 
.937 
12 
Correlation 
Coefficient 
-.135 .093 
6 months 
after trauma 
Age 
Sig. (2-tailed) .677 
12 
.773 
12 
Table 10: Correlations between 2-AG plasma levels and gender / age during the 6-months 
follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.041 .027 
Past traumata 
Sig. (2-tailed) .889 
14 
.930 
13 
Correlation 
Coefficient 
-.475 a 
48 hours 
after trauma 
Somatic injury 
Sig. (2-tailed) .086 
14 
 
13 
Correlation 
Coefficient 
-.029 -.036 
Past traumata 
Sig. (2-tailed) .921 
14 
.902 
14 
Correlation 
Coefficient 
-.574* a 
1 month 
after trauma 
Somatic injury 
Sig. (2-tailed) .032 
14 
 
14 
Correlation 
Coefficient 
-.153 -.039 
Past traumata 
Sig. (2-tailed) .634 
12 
.905 
12 
Correlation 
Coefficient 
-.440 a 
6 months 
after trauma 
Somatic injury 
Sig. (2-tailed) .152 
12 
 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
a. Cannot be computed because at least one of the variables is constant. 
Table 11: Correlations between 2-AG plasma levels and past traumata / somatic injury during 
the 6-months follow-up period after trauma. Traumatized subjects are compared to non-
traumatized controls. 
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.310 a 
Psychiatric history 
Sig. (2-tailed) .281 
14 
 
13 
Correlation 
Coefficient 
.051 .145 
48 hours 
after trauma 
Somatic history 
Sig. (2-tailed) .863 
14 
.637 
13 
Correlation 
Coefficient 
.025 a 
Psychiatric history 
Sig. (2-tailed) .933 
14 
 
14 
Correlation 
Coefficient 
.085 -.457 
1 month 
after trauma 
Somatic history 
Sig. (2-tailed) .774 
14 
.100 
14 
Correlation 
Coefficient 
-.148 a 
Psychiatric history 
Sig. (2-tailed) .645 
12 
 
12 
Correlation 
Coefficient 
.007 .021 
6 months 
after trauma 
Somatic history 
Sig. (2-tailed) .982 
12 
.948 
12 
Table 12: Correlations between 2-AG plasma levels and psychiatric history / somatic history 
during the 6-months follow-up period after trauma. Traumatized subjects are compared to 
non-traumatized controls. 
 
 
Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.167 .130 Intake of any 
medication Sig. (2-tailed) .568 
14 
.673 
13 
Correlation 
Coefficient 
-.332 .233 
48 hours 
after trauma 
Substance abuse 
history Sig. (2-tailed) .246 
14 
.444 
13 
Correlation 
Coefficient 
-.242 -.298 Intake of any 
medication Sig. (2-tailed) .405 
14 
.300 
14 
Correlation 
Coefficient 
-.303 .049 
1 month 
after trauma 
Substance abuse 
history Sig. (2-tailed) .292 
14 
.867 
14 
Correlation 
Coefficient 
-.096 .291 Intake of any 
medication Sig. (2-tailed) .767 
12 
.358 
12 
Correlation 
Coefficient 
-.215 .136 
6 months 
after trauma 
Substance abuse 
history Sig. (2-tailed) .501 
12 
.673 
12 
Table 13: Correlations between 2-AG plasma levels and intake of any medication / substance 
abuse history during the 6-months follow-up period after trauma. Traumatized subjects are 
compared to non-traumatized controls.  
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Time point Demographic variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
.155 -.052 
Marital status 
Sig. (2-tailed) .596 
14 
.866 
13 
Correlation 
Coefficient 
.239 -.044 
48 hours 
after trauma 
Psychiatric family 
history Sig. (2-tailed) .410 
14 
.887 
13 
Correlation 
Coefficient 
-.064 .197 
Marital status 
Sig. (2-tailed) .829 
14 
.500 
14 
Correlation 
Coefficient 
-.046 -.011 
1 month 
after trauma 
Psychiatric family 
history Sig. (2-tailed) .876 
14 
.969 
14 
Correlation 
Coefficient 
.147 .648* 
Marital status 
Sig. (2-tailed) .649 
12 
.023 
12 
Correlation 
Coefficient 
.231 -.101 
6 months 
after trauma 
Psychiatric family 
history Sig. (2-tailed) .470 
12 
.755 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
Table 14: Correlations between 2-AG plasma levels and marital status / psychiatric family 
history during the 6-months follow-up period after trauma. Traumatized subjects are 
compared to non-traumatized controls. 
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Time point Clinical variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.512 a. 
CAPS 
Sig. (2-tailed) .061 
14 
 
13 
Correlation 
Coefficient 
.041 .062 
HAMD 
Sig. (2-tailed) .889 
14 
.841 
13 
Correlation 
Coefficient .122 
-,147 
48 hours 
after trauma 
BDI 
Sig. (2-tailed) .677 
14 
.632 
13 
Correlation 
Coefficient 
-.351 a. 
CAPS 
Sig. (2-tailed) .219 
14 
 
14 
Correlation 
Coefficient 
-.550* -.142 
HAMD 
Sig. (2-tailed) .042 
14 
.628 
14 
Correlation 
Coefficient 
-.300 .175 
1 month 
after trauma 
BDI 
Sig. (2-tailed) .297 
14 
.549 
14 
Correlation 
Coefficient 
-.241 a 
CAPS 
Sig. (2-tailed) .450 
12 
 
12 
Correlation 
Coefficient 
-.198 .075 
HAMD 
Sig. (2-tailed) .560 
11 
.826 
11 
Correlation 
Coefficient 
-,429 .102 
6 months 
after trauma 
BDI 
Sig. (2-tailed) .250 
9 
.753 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
a. Cannot be computed because at least one of the variables is constant. 
Table 15: Correlations between anandamide plasma levels and CAPS / HAMD / BDI during 
the 6-months follow-up period after trauma. Traumatized subjects are compared to non-
traumatized controls. 
 43 
 
Time point Clinical variable 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.364 a. 
CAPS 
Sig. (2-tailed) .201 
14 
 
13 
Correlation 
Coefficient 
.126 .400 
HAMD 
Sig. (2-tailed) .668 
14 
.176 
13 
Correlation 
Coefficient .375 
,105 
48 hours 
after trauma 
BDI 
Sig. (2-tailed) .186 
14 
.733 
13 
Correlation 
Coefficient 
-.244 a. 
CAPS 
Sig. (2-tailed) .401 
14 
 
14 
Correlation 
Coefficient 
-.517 .354 
HAMD 
Sig. (2-tailed) .058 
14 
.214 
14 
Correlation 
Coefficient 
-.259 .476 
1 month 
after trauma 
BDI 
Sig. (2-tailed) .371 
14 
.086 
14 
Correlation 
Coefficient 
-.281 a 
CAPS 
Sig. (2-tailed) .377 
12 
 
12 
Correlation 
Coefficient 
-.199 .429 
HAMD 
Sig. (2-tailed) .558 
11 
.188 
11 
Correlation 
Coefficient 
-,425 -.103 
6 months 
after trauma 
BDI 
Sig. (2-tailed) .254 
9 
.751 
12 
a. Cannot be computed because at least one of the variables is constant. 
Table 16: Correlations between 2-AG plasma levels and CAPS / HAMD / BDI during the 6-
months follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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4.5 Correlations between endocannabinoid levels and brain volume 
changes 
In order to relate changes of endocannabinoid levels to brain plasticity in key regions 
following trauma, correlations between peripheral anandamide and 2-AG levels were 
calculated.  
Significant negative correlations were found for anandamide levels and brain volumes (Table 
17). Left hippocampal volumes at six months were significantly negatively correlated with 
anandamide levels at six months after trauma (r=0.90, p=0.001, Pearson correlation) (Figure 
7). Right hippocampal volumes at six months correlated statistically significant with 
anandamide levels at six months after trauma (r=0.74, p=0.02, Pearson correlation) (Figure 8). 
Fourty-eight hours and one month after trauma, no statistically significant correlations for 
anandamide levels and hippocampal volumes were observed. In the control group, 
anandamide levels were not correlated with hippocampal volumes.  
For 2-AG levels, no correlations with hippocampal volumes were found in any group (Table 
18). 
 
 
Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.03 -.35 
Vol. left hippocampus 
Sig. (2-tailed) .93 
11 
.25 
13 
Correlation 
Coefficient 
-.18 -.38 
48 hours  
after trauma 
Vol. right hippocampus  
Sig. (2-tailed) .60 
11 
.20 
13 
Correlation 
Coefficient 
-.48 -.04 
Vol. left hippocampus 
Sig. (2-tailed) .11 
12 
.90 
14 
Correlation 
Coefficient 
-.49 -.07 
1 month  
after trauma 
Vol. right hippocampus 
Sig. (2-tailed) .10 
12 
.81 
14 
Correlation 
Coefficient 
-.90** .08 
Vol. left hippocampus 
Sig. (2-tailed) .001 
9 
.80 
12 
Correlation 
Coefficient 
-.74* .15 
6 months 
after trauma 
Vol. right hippocampus 
Sig. (2-tailed) .02* 
9 
.65 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
Table 17: Correlations between anandamide plasma levels and hippocampus volumes during 
the 6-months follow-up period after trauma. Traumatized subjects are compared to non-
traumatized controls. 
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Figure 7: Scatterplot of anandamide and left hippocampal volume six months after trauma – 
traumatized (red; r = 0.90, p = 0.001), untraumatized (black; r = 0.15) 
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Figure 8: Scatterplot of anandamide and right hippocampal volume six months after trauma - 
traumatized (red; r = 0.74, p = 0.02), untraumatized (black; r = 0.17) 
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Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.12 -.08 
Vol. left hippocampus 
Sig. (2-tailed) .73 
11 
.80 
13 
Correlation 
Coefficient 
-.31 .02 
48 hours  
after trauma 
Vol. right hippocampus  
Sig. (2-tailed) .36 
11 
.95 
13 
Correlation 
Coefficient 
-.33 -.04 
Vol. left hippocampus 
Sig. (2-tailed) .30 
12 
.89 
14 
Correlation 
Coefficient 
-.38 -.12 
1 month  
after trauma 
Vol. right hippocampus 
Sig. (2-tailed) .23 
12 
.68 
14 
Correlation 
Coefficient 
-.30 .11 
Vol. left hippocampus 
Sig. (2-tailed) .44 
9 
.73 
12 
Correlation 
Coefficient 
-.31 .25 
6 months 
after trauma 
Vol. right hippocampus 
Sig. (2-tailed) .42 
9 
.43 
12 
Table 18: Correlations between 2-AG plasma levels and hippocampus volumes during the 6-
months follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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One statistically significant negative correlation between left amygdala volume at six months 
and anandamide levels at six months after trauma was found in traumatized subjects (r= -0.78, 
p=0.01, Pearson correlation) (Table 19). In non-traumatized controls, for 2-AG levels and 
amygdala volumes at one month follow-up following results were found (Table 20): left 
amygdala volumes at one month correlated statistically significant with 2-AG levels at one 
month after trauma (r=0.55, p=0.041, Pearson correlation) (Figure 9). Right amygdala 
volumes at one month correlated statistically significant with 2-AG levels at one month after 
trauma (r=0.55, p=0.042, Pearson correlation) (Figure 10).  
In traumatized subjects, no correlations existed between 2-AG levels and amygdala volumes 
(Table 20). 
 
 
Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
.07 -.48 
Vol. left amygdala 
Sig. (2-tailed) .84 
11 
.10 
13 
Correlation 
Coefficient 
-.05 -.06 
48 hours  
after trauma 
Vol. right amygdala  
Sig. (2-tailed) .88 
11 
.84 
13 
Correlation 
Coefficient 
-.00 -.12 
Vol. left amygdala 
Sig. (2-tailed) .99 
12 
.68 
14 
Correlation 
Coefficient 
.13 .03 
1 month  
after trauma 
Vol. right amygdala 
Sig. (2-tailed) .70 
12 
.93 
14 
Correlation 
Coefficient 
-.78* -.13 
Vol. left amygdala 
Sig. (2-tailed) .01 
9 
.69 
12 
Correlation 
Coefficient 
-.23 .18 
6 months 
after trauma 
Vol. right amygdala 
Sig. (2-tailed) .56 
9 
.57 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
Table 19: Correlations between anandamide plasma levels and amygdala volumes during the 
6-months follow-up period after trauma. Traumatized subjects are compared to non-
traumatized controls. 
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Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
.33 .05 
Vol. left amygdala 
Sig. (2-tailed) .32 
11 
.88 
13 
Correlation 
Coefficient 
-.12 .26 
48 hours  
after trauma 
Vol. right amygdala  
Sig. (2-tailed) .74 
11 
.40 
13 
Correlation 
Coefficient 
.11 .551* 
Vol. left amygdala 
Sig. (2-tailed) .74 
12 
.041 
14 
Correlation 
Coefficient 
.21 .550* 
1 month  
after trauma 
Vol. right amygdala 
Sig. (2-tailed) .52 
12 
.042 
14 
Correlation 
Coefficient 
.07 -.10 
Vol. left amygdala 
Sig. (2-tailed) .86 
9 
.75 
12 
Correlation 
Coefficient 
.07 .29 
6 months 
after trauma 
Vol. right amygdala 
Sig. (2-tailed) .85 
9 
.37 
12 
* .Correlation is significant at the 0.05 level (Pearson, 2-tailed). 
**. Correlation is significant at the 0.01 level (Pearson, 2-tailed). 
Table 20: Correlations between 2-AG plasma levels and amygdala volumes during the 6-
months follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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Figure 9: Scatterplot of 2-AG and left amygdala volume one month after trauma (controls) 
r=0.55 
p=0.041 
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Figure 10: Scatterplot of 2-AG and right amygdala volume one month after trauma (controls) 
r=0.55 
p=0.042 
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No significant correlations were detected between plasma endocannabinoid levels and 
cingulum volumes (Table 21 + 22). 
 
Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
.003 -.152 
Vol. left ant. cingulate 
Sig. (2-tailed) .992 
11 
.621 
13 
Correlation 
Coefficient 
-.007 .-.120 
Vol. right ant. cingulate  
Sig. (2-tailed) .984 
11 
.696 
13 
Correlation 
Coefficient 
-.209 -.246 
Vol. left med. cingulate 
Sig. (2-tailed) .537 
11 
.418 
13 
Correlation 
Coefficient 
.332 -.143 Vol. right med. 
cingulate  Sig. (2-tailed) .319 
11 
.642 
13 
Correlation 
Coefficient 
.173 -.112 
Vol. left post. cingulate 
Sig. (2-tailed) .612 
11 
.715 
13 
Correlation 
Coefficient 
.370 -.157 
48 hours 
after trauma 
Vol. right post. 
cingulate  Sig. (2-tailed) .262 
11 
.609 
13 
Correlation 
Coefficient 
.000 -.105 
Vol. left ant. cingulate 
Sig. (2-tailed) .999 
12 
.722 
14 
Correlation 
Coefficient 
-.064 -.126 
Vol. right ant. cingulate  
Sig. (2-tailed) .844 
12 
.668 
14 
Correlation 
Coefficient 
.169 -.150 
Vol. left med. cingulate 
Sig. (2-tailed) .599 
12 
.608 
14 
Correlation 
Coefficient 
.221 -.103 Vol. right med. 
cingulate  Sig. (2-tailed) .491 
12 
.727 
14 
Correlation 
Coefficient 
.462 -.259 
Vol. left post. cingulate 
Sig. (2-tailed) .131 
12 
.371 
14 
Correlation 
Coefficient 
.153 -.351 
1 month 
after trauma 
Vol. right post. 
cingulate  Sig. (2-tailed) .634 
12 
.219 
14 
Correlation 
Coefficient 
-.347 -.029 
Vol. left ant. cingulate 
Sig. (2-tailed) .360 
9 
.929 
12 
Correlation 
Coefficient 
-.160 .-.093 
Vol. right ant. cingulate  
Sig. (2-tailed) .680 
9 
.774 
12 
Correlation 
Coefficient 
-.354 -.134 
6 months 
after trauma 
Vol. left med. cingulate 
Sig. (2-tailed) .350 
9 
.678 
12 
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Correlation 
Coefficient 
-.085 -.008 Vol. right med. 
cingulate  Sig. (2-tailed) .828 
9 
.981 
12 
Correlation 
Coefficient 
-.235 -.228 
Vol. left post. cingulate 
Sig. (2-tailed) .543 
9 
.476 
12 
Correlation 
Coefficient 
.096 -.361 Vol. right post. 
cingulate  Sig. (2-tailed) .807 
9 
.248 
12 
Table 21: Correlations between anandamide plasma levels and cingulate volumes during the 
6-months follow-up period after trauma. Traumatized subjects are compared to non-
traumatized controls. 
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Time point Brain region 
 
Trauma N Controls N 
Correlation 
Coefficient 
-.158 .170 
Vol. left ant. cingulate 
Sig. (2-tailed) .642 
11 
.578 
13 
Correlation 
Coefficient 
-.285 .125 
Vol. right ant. cingulate  
Sig. (2-tailed) .396 
11 
.684 
13 
Correlation 
Coefficient 
.016 .126 
Vol. left med. cingulate 
Sig. (2-tailed) .964 
11 
.682 
13 
Correlation 
Coefficient 
.158 .148 Vol. right med. 
cingulate  Sig. (2-tailed) .642 
11 
.629 
13 
Correlation 
Coefficient 
.128 .150 
Vol. left post. cingulate 
Sig. (2-tailed) .708 
11 
.625 
13 
Correlation 
Coefficient 
.082 -.077 
48 hours  
after trauma 
Vol. right post. 
cingulate  Sig. (2-tailed) .811 
11 
.802 
13 
Correlation 
Coefficient 
-.011 .230 
Vol. left ant. cingulate 
Sig. (2-tailed) .972 
12 
.428 
14 
Correlation 
Coefficient 
.033 .272 
Vol. right ant. cingulate  
Sig. (2-tailed) .920 
12 
.346 
14 
Correlation 
Coefficient 
.128 .259 
Vol. left med. cingulate 
Sig. (2-tailed) .691 
12 
.372 
14 
Correlation 
Coefficient 
.060 .446 Vol. right med. 
cingulate  Sig. (2-tailed) .852 
12 
.110 
14 
Correlation 
Coefficient 
.401 .293 
Vol. left post. cingulate 
Sig. (2-tailed) .197 
12 
.310 
14 
Correlation 
Coefficient 
-.007 .046 
1 month  
after trauma 
Vol. right post. 
cingulate  Sig. (2-tailed) .982 
12 
.876 
14 
Correlation 
Coefficient 
.042 .092 
Vol. left ant. cingulate 
Sig. (2-tailed) .915 
9 
.776 
12 
Correlation 
Coefficient 
.233 .047 
Vol. right ant. cingulate  
Sig. (2-tailed) .546 
9 
.886 
12 
Correlation 
Coefficient 
.113 .012 
Vol. left med. cingulate 
Sig. (2-tailed) .772 
9 
.971 
12 
Correlation 
Coefficient 
.596 .175 Vol. right med. 
cingulate  Sig. (2-tailed) .090 
9 
.586 
12 
6 months 
after trauma 
Vol. left post. cingulate Correlation Coefficient 
.103 9 .025 12 
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Sig. (2-tailed) .792 .938 
Correlation 
Coefficient 
.195 .002 Vol. right post. 
cingulate  Sig. (2-tailed) .616 
9 
.996 
12 
Table 22: Correlations between 2-AG plasma levels and cingulate volumes during the 6-
months follow-up period after trauma. Traumatized subjects are compared to non-traumatized 
controls. 
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5. Discussion 
A summary of the results as well as the method is discussed summarizing the statistically 
significant data. We will show the limitations of our study. We will point out future research 
perspectives which appear to be particularly interesting in relation to the role of the 
endocannabinoid system in the pathophysiology of psychic trauma, coping and resilience. 
5.1 Brief summary of results 
A traumatized and a non-traumatized group of 14 subjects were investigated at three time 
points following type I trauma. One month after trauma six subjects were free of symptoms 
and after six months thirteen subjects were free of symptoms. A statistically significant 
difference between the traumatized and the non-traumatized group was found for 2-AG one 
month after trauma. Statistically significant negative correlations existed between 
hippocampal volumes and anandamide levels of traumatized subjects after six months, as well 
as significant positive correlations between amygdala volumes and 2-AG levels of non-
traumatized one month after trauma. 
5.2 Discussion of methods 
5.2.1 Number of participants and types of trauma 
All traumatized subjects had experienced a type I trauma, although the trauma types were 
heterogeneous. It is important to differentiate the type of stress investigated - whether 
somatic, psychic or somato-psychic stress was investigated. Eleven cases were sole psychic 
traumata, whereas three cases consisted of traumata involving physical injuries in addition. 
Three of the traumatized subjects had sustained mild to severe physical injuries additionally to 
the psychic stress they underwent. This might have influenced endocannabinoid levels, thus 
restricting the expressiveness of our results. A completely homogeneous study sample, based 
on sole psychic traumatized subjects would be more desirable for future studies of the 
endocannabinoid system after psychic trauma. It is known that the endocannabinoid system is 
independently activated as a result of traumatic injury itself (Garcia-Ovejero et al. 2009; 
Kaufmann et al. 2009). Seven of our traumatized subjects had a history of past trauma, which 
might have of course influenced reactions of the endocannabinoid system, since past trauma 
can modify the endocannabinoid response. 
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The non-traumatized control group did not statistically differ from the traumatized group in 
terms of age, sex, psychiatric history, family history or history of addiction. For some of the 
investigations at different points of time, N varies between 9 and 14; as the participants did 
not appear at some of the appointments, although they were reminded of their appointments 
by phone calls shortly before. In future investigations, reasons for not-appearing of the 
subjects should be analyzed. Moreover, the comparison with the controls can be discussed in 
relation to environmental ascendancies on the endocannabinoid system which could not be 
identified, as the endocannabinoid system is involved in the regulation of multiple 
physiological responses. 
We regard our study as a pilot experiment, hence the small number of subjects, which needs 
to be studied on greater sample numbers in future.  
5.2.2 Endocannabinoid measurement 
Endocannabinoid measurement was conducted by using high performance liquid 
chromatography-tandem mass spectrometry (HPLC / MS-MS), which was developed by 
Vogeser et al (Vogeser et al. 2006). Pitfalls in measuring 2-AG in human plasma, arising from 
the circumstance that 2-AG undergoes rapid non-enzymatic isomerization to biologically 
inactive 1-AG  were circumvented as recommended by Vogeser and Schelling (Vogeser et al. 
2007). Future endocannabinoid measurements should be accomplished at the same time of the 
day since there is a relationship between endocannabinoid signalling and circadian processes 
(Vaughn et al. 2010). Vaughn et al. described tissue-specific diurnal changes in the amounts 
of endocannabinoids, their degradative and synthetic enymes as well as their receptors. Two 
patterns were found with regard to anandamide concentrations. In hippocampus (Valenti et al. 
2004), among other regions, anandamide concentrations are higher during active periods of 
rats than during inactive periods. An opposite pattern has been observed in CSF and 
hypothalamus, where anandamide concentrations are higher in inactive periods (Murillo-
Rodriguez et al. 2006). Remarkably, tissue contents of 2-AG was found to be in reverse 
relation to anandamide tissue contents; 2-AG concentrations were higher during inactive 
periods in hippocampus among others (Valenti et al. 2004). In a small pilot study, Vaughn et 
al. explored the circadian rhythms of circulating endocannabinoids in humans. Plasma was 
obtained in the late evening, early morning and early evening from five healthy humans who 
had consistent sleep / wake cycles for at least five days prior to sampling.  These results 
indicated that lack of normal sleep produces a significant dysregulation of circulating AEA 
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(Vaughn et al. 2010). Thus, the circadian rhythm of endocannabinoids should certainly be 
taken into account in future studies. 
Regarding the validity of the peripheral (plasma) endocannabinoid levels with regard to 
effects of endocannabinoids in the central nervous system it is difficile to assess this, as no 
papers dealing with this topic were found. Studies so far have solely measured peripheral 
endocannabinoid levels. Naturally, this would be an important issue for further research. 
5.2.3 Data processing for volumetric data analysis 
Discussion of data processing for volumetric data analysis will be treated in the doctor´s 
thesis of the colleague Dino Santangelo de Souza. 
5.3 Discussion of results  
To our knowledge, this is the first prospective study investigating endocannabinoid levels 
after type I trauma in relation to the psychological sequelae and structural changes in brain 
candidate regions involved in the formation of traumatic memories.   
Objective of this study was to investigate the influence of one-time psychic stress on the 
human endocannabinoid system over the course of time. It should be envisioned that research 
in animal models up to date has investigated the endocannabinoid system after stress solely at 
one point of time. Our findings span three points of time after a single psychic trauma. 
 
Diagnoses at the three points of time were distributed as expected. All traumatized subjects 
exhibited an acute stress disorder immediately after trauma. After one month there were four 
traumatized with a fully blown PTSD, whereas six months post trauma only one subject 
remained diagnosed of PTSD. 
Similarly, CAPS, HAMD and BDI scores turned out as anticipated. In traumatized subjects, 
scores decreased with increasing time after the trauma. For controls, scores amounted to no 
pathological results.  
Concerning endocannabinoid levels, there was a statistically significant difference in 2-AG 
levels between the traumatized group and the non-traumatized group one month after trauma. 
Furthermore, a difference was observed when 2-AG levels of traumatized subjects were 
compared one and six months after trauma. Another significant correlation existed between 2-
AG levels and left / right amygdala volumes in controls. 
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5.3.1 Implications for our endocannabinoid results  
2-AG levels were found to be significantly higher in traumatized subjects compared to 
controls one month after trauma, whereas anandamide levels showed no statistic differences 
between groups. Interestingly, this pattern is consistent with the result of Hill et al. in women 
with major depression (Hill et al. 2009) after social stress. Social stress was administered by 
the Trier Social Stress Test, which consists of a public speaking task (mock job interview), 
after subjects have been told that their session will be video- and audiotaped for subsequent 
analysis of paraverbal and nonverbal signs of stress. This paradigma has been shown to 
induce significant and consistent endocrine responses (Kirschbaum et al. 1995). It is self-
evident that the type of social stress in the Trier Social Stress Test cannot be compared to the 
stress of our subjects, who experienced a psychic trauma. Still it is remarkable that results in 
these two investigations are so congruent, which are the only studies on this topic in humans. 
Further studies examining different types of stress in humans are required. 
In this context it is an important question whether the reaction of the endocannabinoid system 
to stress is specific, depending on the type of stressor, or if it is a generalized reaction, 
independent of the type of stressor. In other words, if different patterns of changes in 
endocannabinoid levels occur depending on the type of stressor, or if one pattern of changes 
occurs independently of the kind of stressor. Naturally, the hypothesis of a stressor-dependent 
specific reaction is much more likely. One explanation for the partly inconsistent results 
described in literature may lie in this aspect – the stressors applied were not homotypic, but 
mostly differed from study to study.  
In our study, endocannabinoid levels were measured in peripheral blood (plasma). 
Endocannabinoids play a crucial role in the central nervous system and are also synthesized 
and metabolized in the central nervous system. For comparable results it might be of 
importance whether peripheral or central nervous system levels were measured and the 
location of the sampling for the endocannabinoid determinations in the brain.  
The difference observable between 2-AG levels in traumatized subjects one and six months 
after trauma is consistent with the hypothesis that endocannabinoids act on-demand as a 
protective mechanism, being released after a stressful stimulus to inhibit its consequences 
(Resstel et al. 2009). This corresponds to the findings that six months after trauma there was 
no difference in 2-AG levels between traumatized subjects and controls anymore, and thirteen 
out of fourteen traumatized had fully recovered after six months. Resilience to stress-related 
disease and dysfunction may depend, at least in part, on the physiological integrity and proper 
functioning of the endocannabinoid system, as described in previous studies (Finn 2010). 
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5.3.2  Endocannabinoids levels, neuroplasticity within hippocampus / 
amygdala and trauma 
So far, mainly animal studies are available for interpreting our results concerning the relation 
between anandamide / 2-AG levels and hippocampal / amygdala plasticity,. Study results of 
the endocannabinoid system and its role for regulating processes in hippocampus, amygdala 
as well as in depressive disorders will be propounded as a theoretical foundation for 
interpreting our results.  
 
An impact of endocannabinoids for neurogenesis is assumed by the finding that 
diacylglycerol lipase (diacylglycerol lipase synthesizes 2-AG) knock-out mice show reduced 
neurogenesis, including neurogenesis in the hippocampus (Gao et al. 2010). There is data 
demonstrating that the endocannabinoid system in the hippocampus is sensitive to 
environmental change and suggesting that this system serves as a mediator for experience-
induced plasticity (Hill et al. 2010). Further data of Hill et al. imply that endocannabinoids 
may play a complex role in the regulation of neurogenesis via cell proliferation in the 
hippocampus (Hill et al. 2006).  
Concerning hippocampal plasticity after psychic traumatization, smaller hippocampal 
volumes are discussed either as a susceptibility factor for PTSD or as a consequence of 
trauma. A recent study dealing with this problem in a mouse model of PTSD showed in 
summary that traumatic experience in mice causes a reduction in hippocampus volume 
(Golub et al. 2011). Similarly, a study with 21 participants with PTSD and 17 trauma-exposed 
controls revealed a significant negative correlation between right hippocampal volume and 
PTSD duration, implying that duration of PTSD predicts hippocampal grey matter loss 
(Felmingham et al. 2009). In Vietnam veterans with PTSD, hippocampal volume was directly 
negatively correlated with combat exposure; implying that traumatic stress might lead to 
hippocampus atrophy (Gurvits et al. 1996).  
On the other hand, there is data of an identical twin study supporting the contrary notion, in 
which disorder severity in PTSD patients was negatively correlated with the hippocampal 
volume of both the patient and the patient´s non-traumatized identical twin (Gilbertson et al. 
2002). Similarly, Bonne et al. observed that a smaller hippocampal volume was not a 
necessary risk factor for developing PTSD and did not occur within six months during the 
course of PTSD (Bonne et al. 2001). A recent meta-analysis concluded that hippocampal 
volume reduction is associated with trauma exposure, independent of PTSD diagnosis (Woon 
et al. 2010).  
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The brain seems to have capacity for plasticity in the aftermath of traumatic stress. 
Antidepressant treatment and changes in environment can reverse the sequelae of stress on 
hippocampal neurogenesis, this was investigated on humans with PTSD showing increased 
hippocampal volume after treatment with both paroxetine or phenytoin (Bremner et al. 2008). 
In an animal study, long-term treatment with tricyclic antidepressants lead to an increase of 
CB1 receptor density in the region of hippocampus and hypothalamus (Hill et al. 2006). In 
CB1 knockout mice, the lack of CB1 receptors was associated with an enhanced response to 
stress and deficiency in neuronal plasticity by decreasing brain derived neurotrophic factor 
(BDNF) levels in the hippocampus (Aso et al. 2008). Recent literature also report cannabinoid 
agonists and enhancers to increase serotonin release in the hippocampus besides enhancing 
noradrenergic neuronal firing and activity promoting neurogenesis (Bambico et al. 2009). 
Regarding the connection of hippocampus with emotional stress, particularly childhood stress, 
a study by Frodl et al. compared 43 patients with major depression and 44 age as well as 
gender matched healthy controls using high-resolution MRI (hippocampus, whole brain 
voxel-based morphometry) and assessment of childhood stress. Results were inter alia that 
left hippocampal white matter was smaller in depressive patients, who had experienced 
emotional neglect, compared to those without neglect. Especially interesting, childhood stress 
and brain structure volumes independently predicted a non-favourable course of depression 
(Frodl et al. 2010). Considering depressive episodes as one separate form of stress, another 
investigation of Frodl et al. is noteworthy: 38 patients with major depression and 30 healthy 
controls were examined with high-resolution MRI at baseline and three years later. In 
depressive patients, grey matter density of the hippocampus was significantly reduced 
compared to controls. Patients who had a remission during the three year period had less 
volume reduction than nonremitted patients in the left hippocampus. Thus, these results point 
to neuroplastic stress-related processes that occur in the hippocampus during depressive 
episodes (Frodl et al. 2008). There is also data supporting the hypothesis that mechanisms 
resulting in reduced hippocampal volumes could be related to the development of major 
depression (Frodl et al. 2006) and that the hippocampus with its connections within limbo-
cortical networks may play a crucial role in the pathogenesis of major depression (Frodl et al. 
2002). 
Regarding the role of the endocannabinoid system in depressive disorders, changes in the 
hippocampal endocannabinoid system after stress in relation to the onset of treatment in 
depression were found in rats: McLaughlin et al. implanted bilaterally cannulae directed at the 
dentate gyrus of the hippocampus and administered infusions of either CB 1 receptor agonist, 
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fatty acid amide hydrolase inhibitor, or CB 1 receptor antagonist. Afterwards assessment 
during the forced swim test was conducted. Results indicate that activation of CB 1 receptors 
in the dentate gyrus of the hippocampus results in an antidepressant-like response (increase in 
swimming behaviour) (McLaughlin et al. 2007). In an animal model of chronic unpredictable 
stress, downregulation of endocannabinoid signalling in the nucleus accumbens was measured 
and contributed towards the pathophysiology of depression (Wang et al. 2010). In summary, 
the majority of animal models proposes reduced endocannabinoid levels in depressive 
disorders. 
 
The majority of studies report a hyper-reactivity in PTSD patients (Damsa et al. 2005) for the 
amygdale. A meta-analysis of Woon et al. came to the conclusion that amygdala volumes are 
asymmetrically lateralized after trauma exposure and in PTSD (Woon et al. 2009). A 
mediating role for CB1 receptors in the right basolateral amygdala has been suggested 
regarding short-term extinction of conditioned aversive behaviour (Roche et al. 2007). They 
demonstrated that repeated stress elevates 2-AG levels and enhances short-term 
endocannabinoid signalling at inhibitory synapses in basolateral amygdala in mice (Patel et al. 
2009). Akin, the central amygdala was found to be an important neural substrate subserving 
the interactions between cannabinoids and environmental stress (Patel et al. 2005).  
With regard to the influence of the endocannabinoid system on brain structures, a 
neuroprotective effect of endocannabinoids was described following traumatic brain injury in 
rodents (Mechoulam et al. 2002), as well as an essential role of CB1 proteins in the central 
nucleus of the amygdala for acute fear adaptation of mice (Kamprath et al. 2011). 
 
5.3.3 Implications of brain volume and endocannabinoid results 
Anandamide plasma levels showed strong negative correlations with left and right 
hippocampal volumes in traumatized subjects six months after trauma which was absent in 
controls. To our knowledge, this is the first study investigating the interaction between 
endocannabinoid levels and the hippocampal volume after psychic trauma. The fact, that 
correlations were found exclusively in the traumatized group, and not in the non-traumatized 
controls, suggests that a psychic trauma may initiate changes in both systems which may 
possibly be interrelated. This interpretation is consistent with the data from animal studies 
presented above. 
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Significant positive correlations were found between amygdala volumes and 2-AG levels of 
non-traumatized one month after trauma. This can be interpreted in two variants: either 1. this 
is an incidental finding, as the the correlative analyses were not Bonferroni corrected and false 
positive findings are possible, or 2. this is the manifestation of an anyway existing nexus 
between endocannabinoid levels and amygdala volumes, which is either attributable to 
circumstances not known to us with effect on the endocannabinoid system or is not detected at 
other points of time due to the high variance in the small sample size. Supporting the second 
assumption is the fact that correlations have been found bilaterally for right and left amygdala. 
In our sample no correlations were found between endocannabinoids and anterior, medial and 
posterior cingulate volumes. Perhaps the small sample size might be the reason why no 
correlations between peripheral endocannabinoid levels and cingulum volumes were found. 
Remarkably little is known about the relationship of the endocannabinoid system and the 
cingulate cortex.  
One study regarding this topic describes decreased CB 1 receptor immunopositive glial cells 
in the grey matter of postmortem major depression patients. (Koethe et al. 2007). The study in 
CB 1 receptor knockout mice shows evidence of the involvement of CB 1 receptors in the 
control of GABAergic responses suggests a role of the endocannabinoid system in the 
modulation of anxiety-related disorders (Uriguen et al. 2011).  
Another aspect which needs to be taken into account is the circumstance that the animal 
studies conducted are based on partly mouse or rat models, as mentioned above. Species 
differences have been established for endocannabinoid level changes and effects for rats and 
mice. Therefore, results of animal studies should only be extrapolated with caution to humans. 
Finally, the dose-dependent impact of endocannabinoids has to be postulated when discussing 
endocannbinoid levels and brain volume changes. A dose-effect relationship for 
endocannabinoid levels and anxiety was suggested by Rubino et al. (Rubino et al. 2008) with 
even contrary effects depending on the dose of endocannabinoids. Similarly, it is possible that 
a concentration dependent association exists between endocannabinoid levels and changes of 
hippocampus and amygdale volumes. 
 
5.4 Future perspectives 
In summary, this study investigating changes of peripheral endocannabinoid levels and  
volumes of key regions involved in the pathophysiology of traumatic memories during six 
months after a single psychic trauma yields interesting results, which are mainly in line with 
 64 
the conclusions of animal models. In view of the fact that to our knowledge this is the first 
study exploring the endocannabinoid system in healthy humans after psychic stress, future 
studies with larger samples and an assessment of further clinical variables (e.g. aversive 
memories), other endocrine stress responses (e.g. HPA axis), additional brain areas, separate 
investigations of brain volumes (MRI) versus function (fMRI) and different types of traumatic 
events (e.g. type 1 vs. type 2 trauma) or stressful life-events (e.g. single, repeated or chronic) 
would be worthwhile. 
 
In future studies, endocannabinoid levels should probably be measured at a standardized time 
of each day, taking the putative circadian rhythm of endocannabinoid levels into account 
(Vaughn et al. 2010). Moreover, there is evidence of an influence of gender on 
endocannabinoid mediated effects (Atkinson et al. 2010). Hence, results of males and females 
should perhaps be interpreted separately. Furthermore, the question of peripheral 
endocannabinoid measurements versus validity for effects in the central nervous system 
should be incorporated in future studies. 
Furthermore, the type of stressor should be standardized and as homotypic as possible with 
regard to somatic versus psychic stress, intensity, predictability and duration. 
It would also be interesting to correlate endocannabinoid levels with the degree of extinction 
of aversive memories in future studies. In order to scrutinize existing and future related 
studies for the treatment of PTSD, further clinical trials are necessary which investigate the 
potential therapeutic efficacy of drugs that enhance endocannabinoid levels in anxiety 
disorders including PTSD (Finn 2010). 
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6. Conclusion 
As a concluding remark it can be stated that the endocannabinoid system is an intriguing 
regulatory system, which is still in its infancy regarding the theoretical knowledge about its 
nature and interaction with other neurotransmitters, brain regions and behavioral 
consequences. Anyhow it appears to play a pivotal role in the neural response and plasticity 
after stress, and in consequence it modifies pathophysiological processes which occur in 
conditions like PTSD, anxiety, depression as well as it may exert a neuroprotective function. 
Most probably it can contribute to a psychophysiological equilibrium only as long as it works 
within a physiological range. Regarding research data, it is salient that studies are 
preponderantly based on animal models. Our investigation provides first data about changes 
in endocannabinoid regulation after psychic stress in humans, and future studies should aim at 
revealing more detailed information about different endocannabinoids, their homeostatic role 
and specifity. Potential implications for prophylactic or therapeutic use after stress 
respectively trauma seem promising. 
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7. Summary 
The endocannabinoid system has emerged as one of the most important facilitators of stress 
adaptation in the body. So far, little to no research took place concerning the endocannabinoid 
response to stress in humans. In this study, we investigated the influence of a type I trauma on  
endocannabinoid plasma levels in humans over a period of 6 months, compared with non-
traumatized controls. We measured endocannabinoid plasma levels (using high performance 
liquid chromatography-tandem mass spectrometry) as well as hippocampal and amygdala 
volumes in fourteen participants who had experienced a psychic trauma and developed an 
acute stress disorder. Fourteen healthy non-traumatized age- and gender-matched controls 
were studied in comparison over a 6 months period. Data were collected at three points of 
time: within 48 hours after the traumatic event, after one month and after six months. At each 
point of time a psychiatric interview was conducted and the Clinician Administered PTSD 
Scale (CAPS), HAMD and BDI were rated. When 2-Arachidonoylglycerol (2-AG) levels 
were compared between traumatized subjects and non-traumatized controls, there was a 
statistical significant difference one month after trauma (p=0.046). Regarding 
endocannabinoid levels over the course of time, 2-AG decreased in the trauma group between 
one month and six months after the initial trauma. This finding was in line with the hypothesis 
that endocannabinoids act on-demand as protective mechanism, being released after a 
stressful stimulus to inhibit the development of posttraumatic sequelae. In traumatized 
subjects, anandamide levels after six months showed a strong negative correlation with 
hippocampal volumes at this time point. A statistically significant negative correlation 
between left amygdala volume at six months and anandamide level at this time point in 
traumatized subjects was found. In non-traumatized controls, remarkably, there were positive 
correlations of 2-AG levels and amygdala volumes one month after trauma, which were not 
detected at the other time points. In contrast, endocannabinoid levels were neither correlated 
with any demographic and clinical variable, nor with volumes of cingulate regions. 
In conclusion, the results of our study point to a delayed and possibly regulatory response of  
the endocannabinoid system after a single psychic trauma over the course of six months in 
humans. Moreover, the data point to a genuine relation of peripheral endocannabinoid levels 
possibly reflecting central endocannabinoid activity and neuroplasticity in brain key regions 
involved in the generation of traumatic memories, i.e. hippocampus and amygdale. 
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8. Zusammenfassung 
Das Endocannabinoidsystem hat sich als eines der bedeutendsten Systeme hinsichtlich der 
Anpassung an Stress in biologischen Systemen erwiesen. Bislang liegen wenig bis keine 
Forschungsergebnisse zu Veränderungen des humanen Endocannabinoidsystem nach 
psychischem Stress vor. In vorliegender Studie untersuchten wir im Vergleich mit 
untraumatisierten Kontrollprobanden über einen Zeitraum von sechs Monaten den Einfluss 
eines Typ–I-Traumas auf menschliche Endocannabinoidkonzentrationen im Plasma. Wir 
bestimmten die Endocannabinoidwerte im Plasma (mittels einer Kombination von 
Hochdruck-Flüssigkeitschromatographie und einem massenspektrometrischen 
Tandemdetektionsverfahren) als auch Hippocampus- und Amygdalavolumina bei 14 
Probanden, die ein psychisches Trauma innerhalb 48 Stunden vor Rekrutierung erlebt hatten, 
und eine akute Belastungsreaktion entwickelt hatten. Zum Vergleich wurden 14 
untraumatisierte alters- und geschlechtsgematchte Kontrollprobanden über einen Zeitraum 
von sechs Monaten untersucht. Die Daten wurden zu drei Unterschungszeitpunkten erhoben: 
innerhalb von 48 Stunden nach dem Trauma, einen Monat später und sechs Monate später. Zu 
jedem Untersuchungszeitpunkt wurde ein „Clinician Administered PTSD Scale“ Interview 
(CAPS) durchgeführt, sowie HAMD und BDI Skalen erhoben. Es gab einen statistisch 
signifikanten Unterschied zum Zeitpunkt 1 Monat nach Trauma bei den 2-AG Werten 
zwischen den traumatisierten Probanden und untraumatisierten Kontrollprobanden (p=0,046). 
Bezüglich der Endocannabinoidwerte über den Zeitverlauf kam es zu einem Abfall von 2-AG 
in der Gruppe der traumatisierten Probanden zwischen einem Monat und sechs Monaten nach 
dem initialen Trauma. Dieser Befund stimmte mit der Hypothese überein, dass 
Endocannabinoide bedarfsorientiert nach dem Auftreten eines Stressstimulus als protektiver 
Mechanismus freigesetzt werden, um die Entwicklung posttraumatischer Folgen zu 
begrenzen. Bei den traumatisierten Probanden korrelierten die Anandamidwerte zum 
Zeitpunkt sechs Monate nach Trauma hochsignifikant negativ mit den Hippocampusvolumina 
zu diesem Zeitpunkt. Eine statistisch signifikante negative Korrelation fand sich bei den 
traumatisierten Probanden zwischen linkem Amygdalavolumen nach sechs Monaten und 
Anandamidwerten zu diesem Zeitpunkt. Bei den untraumatisierten Kontrollprobanden gab es 
bemerkenswerterweise positive Korrelationen zwischen 2-AG Werten und den 
Amygdalavolumina nach einem Monat, die zu den anderen Zeitpunkten nicht festgestellt 
wurde. Im Gegensatz dazu gab weder Korrelationen von Endocananbinoidwerten mit den 
demographischen bzw. klinischen Variablen, noch mit den Cingulumvolumenwerten. 
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Abschließend lässt sich sagen dass die Ergebnisse unserer Studie über den Zeitraum von 
sechs Monaten auf eine verzögerte und möglicherweise regulierende Antwort des 
Endocannabinoidsystems auf ein einmaliges psychisches Trauma beim Menschen hinweisen. 
Zudem deuten die Daten auf einen echten Zusammenhang der peripheren 
Endocannabinoidspiegel hin, der möglicherweise die Beteiligung der Aktivität des 
Endocannabinoidsystems im ZNS und der Neuroplastizität in Schlüsselhirnregionen, sprich in 
Hippocampus und Amygdala an der Formation traumatischer Erinnerungen, widerspiegelt.  
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9. Appendix 
9.1 Information sheet for participants and informed consent 
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Klinik und Poliklinik für Psychiatrie und 
Psychotherapie-Innenstadt  
Direktor: Prof. Dr. med. Hans-Jürgen Möller 
 
 
 
Klinikum der Universität München  •  Klinik und Poliklinik für Psychiatrie und Psychotherapie 
Nußbaumstraße 7  •  D-80336 München 
  
 
Projektleiter: PD Dr. F. Padberg 
Telefon  089/5160-5879, Fax 089/5160-5882 
 
Verantwortlich für die Durchführung: Dr. T. Krauseneck 
Telefon: 089/5160-5512; Fax: 089/5160-5882 
 
Probanden-Informationsblatt 
 
für die Teilnahme an der Studie: 
Akute Belastungsreaktion und psychische Traumatisierung – Untersuchungen 
zur Neurobiologie und neuronalen Konnektivität im Verlauf 
 
Sehr geehrte Probandin, sehr geehrter Proband, 
 
Sie haben sich zur Teilnahme an unserer Probandenstudie entschieden. Im folgenden 
Abschnitt wollen wir Sie über Fragestellung, Ablauf und mögliche Nebenwirkungen der 
geplanten Untersuchung ausführlich informieren. 
 
1. Fragestellung der Studie: 
In der vorliegenden Studie geht es darum, strukturelle Veränderungen im Gehirn von 
Patienten darzustellen, die ein traumatisches Ereignis erlebt haben. Hierbei gilt das 
Hauptinteresse dem Mandelkern und dem Hippokampus. Dies sind Hirnregionen, die für die 
Verarbeitung emotionaler Inhalte wichtig sind und die durch das körpereigene Hormon 
Cortisol beeinflusst werden. Es gibt bereits Hinweise darauf, dass Patienten die in Folge 
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eines traumatischen Ereignisses an einer so genannten posttraumatischen 
Belastungsstörung erkranken, Auffälligkeiten in diesen Hirnarealen aufweisen.  
Zum anderen gibt es Hinweise, dass erhöhte Cortisol-Spiegel im Blut unmittelbar nach einem 
traumatischen Erlebnis das Risiko vermindern, später eine posttraumatische 
Belastungsstörung (Post Traumatic Stress Disorder, PTSD) zu entwickeln.  
Anfang der neunziger Jahre wurde eine neue Gruppe körpereigener Botenstoffe, die so 
genannten Anandamide oder auch Endocannabinoide, entdeckt. Diese Botenstoffe spielen 
bei körpereigenen Regulationsprozessen der Kognition, der Schmerzwahrnehmung, der 
Stimmungsregulation und dem Gedächtnis eine Rolle. Die bisherige klinische Erfahrung 
deutet auf einen Zusammenhang dieses körpereigenen Botenstoffes bei der Verarbeitung 
traumatischer Erfahrungen hin. 
In der vorliegenden Studie sollen nun diese körpereigenen Prozesse zum einen mittels einer 
bildgebenden Technik und zum anderen mittels Bluttests untersucht werden. Die in den 
Untersuchungen gewonnenen Erkenntnisse sollen dabei helfen, psychische 
Belastungsfolgen zukünftig differenzierter zu erkennen und therapeutische Ansätze zu 
entwickeln. 
 
2. Ablauf der Untersuchung: 
ZUR BILDGEBENDEN TECHNIK: Bei der sog. DTI-Untersuchung werden die oben 
angeführten Hirngebiete dargestellt. Diese Untersuchung ist eine Weiterentwicklung der 
Ihnen möglicherweise bekannten Kernspintomographie (MRT) die mit Hilfe von 
magnetischen Feldern durchgeführt wird und somit ohne Strahlenbelastung für Sie ist.  
Es werden insgesamt maximal 3 DTI-Untersuchungen durchgeführt. Die erste soll innerhalb 
von 48 h nach dem stattgefundenen Trauma und die zweite nach vier Wochen durchgeführt 
werden. Sollte es bei Ihnen zur Ausbildung einer posttraumatischen Belastungsstörung 
kommen, so wird nach einem halben Jahr (6 Monate) die dritte Untersuchung durchgeführt. 
Die DTI - Untersuchung wird jeweils etwa 30 Minuten dauern. In der Zeit dazwischen werden 
verschiedene psychologische Tests durchgeführt werden. Diese dienen dazu, begleitende 
psychiatrische Erkrankungen zu erkennen, Ihren momentanen psychischen Zustand zu 
erfassen und eine evtl. familiäre Belastung darzustellen.  
ZUM BLUTTEST: Hierbei sollen mit Hilfe der Untersuchung der Stimulierbarkeit des 
Streßhormons Cortisol weitere Informationen über gestörte Regelsysteme bei 
psychiatrischen Erkrankungen erhalten werden. Zu diesem Zweck wird zusätzlich zu den 
klinisch notwendigen Routineuntersuchungen eine Hormonuntersuchung, der so genannte 
Low dose Dexamethason Suppressionstest  (abgekürzt Low-dose DEX-Test)  durchgeführt. 
Im Rahmen dieser Untersuchung, die seit vielen Jahren an einer großen Zahl von Patienten 
in psychiatrischen Kliniken durchgeführt wurde, wird Ihnen am Vortag der Untersuchung 
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zunächst um 8.00 Uhr 10 ml Blut entnommen. Um 23.00 Uhr nehmen Sie eine Tablette 
0,5mg Dexamethason einmalig ein. Dexamethason ähnelt einem körpereigenen Hormon, 
dem Streßhormon Cortisol. Nach einer einmaligen Einnahme sind keine Nebenwirkungen zu 
erwarten. Am folgenden Tag werden Ihnen um 8.00 Uhr und um 16.00 Uhr jeweils 10ml Blut 
entnommen. Diese Untersuchung kann Ihnen im weiteren Behandlungsverlauf noch ein 
weiteres Mal vier Wochen und gegebenenfalls sechs Monate nach dem Trauma empfohlen 
werden. 
Um die Rolle und die Funktion der körpereigenen Anandamide genauer zu untersuchen 
werden Ihnen im Rahmen der ersten Blutentnahme für den Low-dose DEX-Test und dann 
nochmals zu den Nachsorgeterminen während der ersten vier Wochen und ggf. erneut nach 
sechs Monaten jeweils 5 ml Blut entnommen. 
Unabhängig von der Studienteilnahme werden die in unserem Hause üblichen 
Laboruntersuchungen einschließlich Drogenscreening bei Aufnahme und im 
Behandlungsverlauf durchgeführt. Ihre behandelnde Ärztin / ihr behandelnder Arzt wird Ihnen 
diese gerne näher erläutern. Die Ergebnisse dieser Untersuchung haben auf die Behandlung 
Ihrer Erkrankung keinen unmittelbaren Einfluß.  
 
3. Mögliche Nebenwirkungen und Risiken: 
Die bildgebende Untersuchung ist für Sie mit keiner Strahlenbelastung verbunden. 
Schädigende Wirkungen der Kernspintomographie sind nach dem derzeitigen Stand der 
Wissenschaft nicht bekannt. Eine Gabe von Kontrastmittel ist nicht nötig. Einige Patienten 
können mit dieser Methode nicht untersucht werden. Dies betrifft Patienten die einen 
Herzschrittmacher haben, in deren Körper sich Metallteile befinden, die spezielle 
Tätowierungen oder permanentes Make-up haben. Auch bei Schwangeren sowie bei 
Patienten die an schwerer Platzangst leiden sollte diese Untersuchung nur nach 
Rücksprache mit dem Arzt durchgeführt werden. Die Bluttests sind für Sie mit keinem Risiko 
verbunden, dass über das Risiko einer normalen Blutentnahme hinausgeht. Falls Ihr 
klinischer Zustand sich verschlechtert oder andere schwerwiegende Beschwerden auftreten 
sollten, wird die Studie umgehend abgebrochen.  
Falls bei Ihnen körperlicher Erkrankungen oder eine Schwangerschaft besteht, teilen Sie 
dies bitte umgehend dem Prüfarzt mit. Teilen Sie dem Prüfarzt bitte umgehend mit, ob sie 
dauerhaft oder auch nur vorübergehend ein Medikament eingenommen haben.  
 
4. Versicherungsschutz 
Es muss für diese Studie keine Versicherung für die Probanden abgeschlossen werden, da 
die Studie nicht unter das Arzneimittelgesetz fällt und die Risiken im Rahmen der Studie nur 
gering sind. Für sonst übliche Risiken wie z.B. Wegeunfälle besteht für Sie 
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Versicherungsschutz bei der Firma Gerling (Adresse) unter der Versicherungsnummer 22-
7271666. Im Schadensfall können Sie sich direkt an den Versicherer wenden und Ihre 
Ansprüche selbständig geltend machen. Bitte unterziehen Sie sich während der Dauer der 
Studie einer anderen medizinischen Behandlung nur im Einvernehmen mit den 
Untersuchungsleitern; ausgenommen davon sind Notfälle. Dies gilt auch für die zusätzliche 
Einnahme von Medikamenten. Auch müssen Sie eine Gesundheitsschädigung, die als Folge 
der klinischen Prüfung eingetreten sein könnte, den Untersuchungsleitern und der oben 
genannten Versicherungsgesellschaft  unverzüglich mitteilen. Falls Sie während der 
Teilnahme an der Studie eine Gesundheitsschädigung erleiden, wird die 
studiendurchführende Klinik jegliche medizinische Behandlung sowie eine eventuelle 
Überweisung an geeignete medizinische Einrichtungen sicherstellen.  
 
5. Vertraulichkeit/Datenschutz: 
Die im Rahmen der Studie erhobenen Daten zu Ihrer Person und zu Ihrem Befund 
werden in verschlüsselter Form gespeichert und streng anonym ausgewertet. Dazu 
wird Ihren Daten eine Studiennummer zugeteilt. Eine Rückverfolgung der Daten zu 
Ihnen beispielsweise über Ihre Initialen oder Ihr Geburtsdatum ist nicht möglich. Nur 
die Prüfer sowie autorisierte Personen der Gesundheits- bzw. Strahlenschutzbehörden 
haben im Rahmen der entsprechenden gesetzlichen Vorschriften Zugang zu den 
vertraulichen Daten, in denen Sie namentlich genannt werden. Diese Personen 
unterliegen der Schweigepflicht und sind zur Beachtung des Datenschutzes 
verpflichtet. Die Weitergabe der Daten im In- und Ausland erfolgt ausschließlich zu 
statistischen und wissenschaftlichen Zwecken, und Sie werden ausnahmslos darin 
nicht namentlich genannt. Auch in etwaigen Veröffentlichungen der Daten dieser 
klinischen Prüfung werden Sie nicht namentlich genannt. 
 
Die Therapieempfehlung Ihres behandelnden Arztes erfolgt unabhängig von den gerade 
beschriebenen Untersuchungen. Diese dienen ausschliesslich der Grundlagenforschung und 
haben keine Bedeutung für die individuelle Therapieplanung. Es könnte sich evtl. die 
Möglichkeit für Ansatzpunkte für eine Pharmakotherapie bieten. Durch den Vergleich der 
Ergebnisse der Untersuchungen mit den Ergebnissen anderer Patientengruppen und von 
gesunden Probanden sollen sich Hinweise zum genaueren Verständnis einer psychischen 
Traumatisierung, auf den Therapieverlauf sowie auf den weiteren Verlauf einer eventuell 
daraus entstehenden Erkrankung gewinnen lassen. 
Ihre Teilnahme an der Studie ist freiwillig und Sie haben das Recht, sie jederzeit zu beenden, 
ohne dass Ihnen irgendwelche Nachteile daraus entstehen. Sollten Sie Ihr Einverständnis 
zur Untersuchung widerrufen, werden die bis dato erhobenen Daten unter den weiter 
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oben angeführten Einschränkungen weiterhin genutzt. Die Untersuchung kann auch 
jederzeit ohne Angabe von Gründen vom Untersuchungsleiter beendet werden. 
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Klinikum der Universität München 
Klinik und Poliklinik für Psychiatrie und 
Psychotherapie-Innenstadt  
Direktor: Prof. Dr. med. Hans-Jürgen Möller 
 
 
 
Klinikum der Universität München  •  Klinik und Poliklinik für Psychiatrie und Psychotherapie 
Nußbaumstraße 7  •  D-80336 München   
 
Projektleiter: PD Dr. F. Padberg 
Telefon  089/5160-5879, Fax 089/5160-5882 
 
Verantwortlich für die Durchführung: Dr. T. Krauseneck 
Telefon: 089/5160-5899; Fax: 089/5160-5322 
 
Probandeneinverständniserklärung  
für die Teilnahme an der Studie 
 
Akute Belastungsreaktion und psychische Traumatisierung – Untersuchungen 
zur Neurobiologie und neuronalen Konnektivität im Verlauf 
 
Das Informationsblatt wurde mir ausgehändigt und ich habe es sorgfältig gelesen. Zu der mir 
vorgeschlagenen Studie habe ich noch folgende Fragen: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
Es bestand genügend Zeit, um meine Fragen zu beantworten.  
 
Ich bin über den Ablauf und mögliche Nebenwirkungen der obengenannten Untersuchung 
aufgeklärt worden und gebe meine Zustimmung zur Teilnahme an der Studie. Ich kann mein 
Einverständnis zu jedem Zeitpunkt, ohne Angabe von Gründen, zurücknehmen. 
 
Ich erkläre mich freiwillig mit der Teilnahme an der Studie einverstanden. Ich wurde über den 
Untersuchungsablauf unterrichtet. Meine zusätzlichen Fragen wurden beantwortet. 
 
München, den ____________ 
 
________________________  _________________________________ 
Name und Unterschrift des Probanden Name und Unterschrift des aufklärenden Arztes 
 
Die Angaben zur Verwendung und Verschlüsselung meiner Daten habe ich gelesen. Ich 
erkläre mich freiwillig mit der Speicherung und Verwendung meiner Daten im Rahme 
der Studie einverstanden.  
 
München, den ________________ _____________________________ 
 Name und Unterschrift des Probanden 
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9.2 Exclusion criteria 
Ausschlusskriterien 
 
Eine Studienteilnahme war nicht möglich, wenn ein oder mehrere der folgenden Kriterien erfüllt waren: 
 
• Bestehen einer Betreuung/ Geschäftsunfähigkeit 
• Bestehende Schwangerschaft 
• Implantierte Metallteile die eine MRT-Untersuchung unmöglich machen 
• Drogen-, Medikamenten- oder Alkoholmissbrauch zum Zeitpunkt der Studie 
• Zerebrovaskuläre Erkrankungen  
• Demenz (DSM IV/ICD 10-Kriterien) 
• Wiederholte Schädel-Hirn-Traumata in der Anamnese 
• Hinweise auf strukturelle Schädigung der Basalganglien oder des Hirnstamms 
• Schwere neurologische Erkrankungen (wie Diskusprolaps in den letzten 6 Monaten, 
Polyneuropathien, Parkinson-Syndrom, Epilepsie, Demenz, systemische neurologische 
Erkrankungen, zerebrovaskuläre Erkrankungen, Schlaganfall in der Anamnese, wiederholte 
zerebrale Ischämien mit einer stufenweisen Verschlechterung, erhöhter Hirndruck, 
Normaldruckhydrozephalus) 
• Schwere psychiatrische Erkrankungen (mit Ausnahme der Depression)  
• Akute Suizidalität oder Suizidversuch in der Vorgeschichte 
• Schwere internistische Erkrankungen (wie manifeste arterielle Hypertonie, schwere 
Herzerkrankungen, Herzschrittmacher, respiratorische Insuffizienz) 
• Maligne Erkrankungen jeglicher Art 
• Schwere aktive Infektionskrankheiten 
• Knochenerkrankungen (wie M. Paget, Osteoporose mit Spontanfrakturen, frische Frakturen) 
• Andere Umstände, die nach Meinung des Prüfarztes gegen eine Teilnahme des Patienten an 
dieser Studie sprechen 
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